Preclinical Models of Neuroendocrine Neoplasia

Andrew J. H. Sedlack 1,2,* Kimia Saleh-Anaraki 3, Suresh Kumar 3, Po Hien Ear 4, Kate E. Lines 5, Nitin Roper 3, Karel Pacak 6, Emily Bergsland 7, Dawn E. Quelle 8, James R. Howe 4, Yves Pommier 3 and Jaydira del Rivero 3,*

1 National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health (NIH), Bethesda, MD 20892, USA
2 Medical Scientist Training Program, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
3 National Cancer Institute, NIH, Bethesda, MD 20892, USA
4 Department of Surgery, University of Iowa, Iowa City, IA 52242, USA
5 Oxford Center for Diabetes, Endocrinology, and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK
6 Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA
7 University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA
8 Department of Neuroscience and Pharmacology, University of Iowa, Iowa City, IA 52242, USA
* Correspondence: jaydira.delrivero@nih.gov

Simple Summary: Neuroendocrine neoplasia comprise many distinct and rare subtypes of cancers. Preclinical models are essential for improving understanding of these diseases because clinical data is scarce. We review available preclinical models across a wide spectrum of neuroendocrine neoplasia (including those affecting the lungs, gastrointestinal system, prostate, and adrenal glands). We consider models of varying complexity and accuracy, covering both in vitro models such as cell lines and 3D models, and in vivo models such as xenografts and genetically-engineered mouse models. Better access and understanding of these models as provided in this work will help to enable research into pathology and treatment across the spectrum of neuroendocrine neoplasia.

Abstract: Neuroendocrine neoplasia (NENs) are a complex and heterogeneous group of cancers that can arise from neuroendocrine tissues throughout the body and differentiate them from other tumors. Their low incidence and high diversity make many of them orphan conditions characterized by a low incidence and few dedicated clinical trials. Study of the molecular and genetic nature of these diseases is limited in comparison to more common cancers and more dependent on preclinical models, including both in vitro models (such as cell lines and 3D models) and in vivo models (such as patient derived xenografts (PDXs) and genetically-engineered mouse models (GEMMs)). While preclinical models do not fully recapitulate the nature of these cancers in patients, they are useful tools in investigation of the basic biology and early-stage investigation for evaluation of treatments for these cancers. We review available preclinical models for each type of NEN and discuss their history as well as their current use and translation.

Keywords: neuroendocrine tumor; genetically-engineered mouse model; organoid; cell line; small cell lung cancer; castration-resistant prostate cancer; xenograft

1. Introduction

Neuroendocrine neoplasia (NENs) comprise a spectrum of malignant neoplasia that originate in neuroendocrine cells and can affect almost any part of the body. They vary from low Ki-67 level neuroendocrine tumors (NETs) to high Ki-67 level grade 3 NETs and biologically distinct neuroendocrine carcinomas (NECs). Although patients with
low-grade tumors can survive many years, their high-grade counterparts are extremely aggressive and have a dismal outcome. As neuroendocrine cells are ubiquitous in our body, NENs can form in different organs including the gastrointestinal (GI) tract, pancreas, lungs, gallbladder, thymus, thyroid gland, testes, prostate, ovaries, and skin. NETs occur most often in the gastroenteropancreatic (GEP) system (51–67%) and lungs (21–27%) [1–3]. Gastroenteropancreatic NETs (GEP-NETs) occur most often in the small intestine (30–31%), rectum (26–29%), pancreas (12–13%), or appendix (6%) [2,3].

NENs can cause a broad range of symptoms based on type, location and secretion of hormones. They are classified as functional or non-functional NENs based on whether or not, respectively, they secrete hormones. Most functional NENs are NETs [1,4,5]. Rates of functionality differ depending on the type of NET: 10% of gastrointestinal, 10% of pulmonary, 10–30% of pancreatic [6,7], and 40% of adrenal [8]. While functional NETs may cause significant clinical signs and symptoms that often leads to earlier diagnosis, presentation varies widely depending on the hormone secreted. Carcinoid syndrome, which occurs in up to 20% of patients with small bowel (SB)NETs, is associated with flushing, abdominal pain, diarrhea, bronchoconstriction, and carcinoid heart disease [3]. In contrast, due to the lack of signs and symptoms, non-functional NETs are often diagnosed in the later stages after the occurrence of symptoms related to the mass effect of the tumor or metastases [9]. Moreover, while most NETs are sporadic, 20% are associated with hereditary genetic syndromes, such as multiple endocrine neoplasia type 1, von Hippel-Lindau, tuberous sclerosis, and neurofibromatosis type 1 [1].

NENs have been recognized for at least a century. They are considered an orphan disease (i.e., have a prevalence of <200,000 in the United States), and hence research is relatively sparse [10]. Disappointingly, survival of patients with NENs has not changed appreciably over the past three decades in either the USA or UK and without robust preclinical models, future drug development and our understanding of the underlying pathophysiology can be challenging. Indeed, an unmet need is improvement in the available models for each NEN subtype (i.e., both their number and authentic recapitulation of the human disease) that will enable rigorous investigation of their derivation, biology, behavior, and new treatment strategies.

For instance, small cell prostate carcinoma resembles neuroendocrine small cell lung cancer (SCLC) and makes up a minor fraction (<2%) of prostate cancers [11–13]. However, systemic therapies for prostate adenocarcinoma (the most commonly diagnosed type) are currently based on inhibition of androgen receptor signaling, which unfortunately leads to partial or complete neuroendocrine transdifferentiation in 10–20% of patients and accompanying development of resistance to hormonal treatment [13–15]. This highlights the biomedical relevance of studying neuroendocrine cell differentiation, but preclinical models of de novo small cell prostate carcinoma (natively neuroendocrine) are limited except for xenografts [16,17]. The comparatively high incidence of treatment-induced neuroendocrine prostate cancer (t-NEPC) makes up an increasing fraction of both prostate and neuroendocrine tumors in treatment (especially within neuroendocrine carcinomas but also of NENs overall) [13], warranting development of better models for investigation.

Disease models are indispensable in yielding meaningful insights into the etiology and biology of human neoplasms and to develop novel treatments. Herein, we consider the existing in vitro models of NENs including human-derived cell lines and 3D models (such as organoids, spheroids, and tumoroids), and in vivo NEN models including patient-derived xenografts (PDXs) and genetically engineered mouse models (GEMMs).

While more models are needed, this review also summarizes how those available have nonetheless provided valuable insights into the pathogenesis and natural history of human NENs. Moving forward, it will be increasingly important that current and new NEN models be used to study methods of early tumor detection, molecular predictors of tumor behavior that can be leveraged clinically, and responses (including mechanisms) to novel targeted drug therapies.
2. Results

2.1. Cell Lines

Cell line propagation is the oldest and simplest method of tissue culture. Their convenience makes them one of the more accessible and flexible strategies for basic mechanistic research and drug screening. However, the huge gap between the microenvironment experienced by tumors in vivo and in monolayer or spheroid culture on polystyrene limits their efficacy as a model system. Less aggressive cancers tend to be more reliant on particular environmental cues and often prove difficult or impossible to culture as homogeneous cell lines, leading to overrepresentation of poorly differentiated carcinomas and other rapidly growing forms in cell line libraries [18]. Cell lines are presented in Table 1.

Table 1. Human neuroendocrine neoplasm-derived cell lines.

| Cell Line   | Source 1 | Type               | # Refs | Year  | References |
|-------------|----------|--------------------|--------|-------|------------|
| KNA         | AM       | PCC                | 3      | 1998  | [19]       |
| KAT45       | AM       | benign             | -      | 1998  | [20]       |
| hPheo1      | AM       | benign             | -      | 2013  | [21]       |
| NEC-DUE3    | An       | small cell carcinoma | LN met | 1    | 2018       |
| NEC913, NEC1452 | AP, C | LN met             | -      | 2019  | [23]       |
| COLO320     | C        | colorectal w NE features | 18    | 1979  | [24]       |
| LCC-18      | C        | colon              | 1      | 1991  | [25]       |
| NEC-DUE2    | C        | lymph node met     | 1      | 2014  | [26]       |
| HROC57      | C        | PD large cell carcinoma | 1    | 2018  | [27]       |
| SS-2        | C        | ascending colon carcinoma | 1    | 2019  | [28]       |
| EPG1        | CB       | -                  | -      | 1992  | [29]       |
| ECC18       | E        | esophageal         | 1      | 1993  | [30]       |
| TYUC-1      | E        | small cell carcinoma | 3    | 2015  | [31]       |
| NEC-DUE1    | GEJ      | carcinoid hepatic met | 1    | 2014  | [26]       |
| PTJ64p      | JT       | benign             | -      | 2013  | [32]       |
| OAT         | L        | SCLC               | -      | 1971  | [33]       |
| SHP-77      | L        | SCLC               | 17     | 1978  | [34]       |
| DMS-273     | L        | SCLC               | 18     | 1978  | [35]       |
| COR-L24     | L        | SCLC               | 7      | 1985  | [36]       |
| COR-L47     | L        | SCLC               | 9      | 1985  | [36]       |
| COR-L51     | L        | SCLC               | 7      | 1985  | [36]       |
| SCLC-21H    | L        | SCLC               | 13     | 1987  | [37]       |
| CPC-N       | L        | SCLC               | 10     | 1992  | [38]       |
| UMC-11      | L        | carcinoid          | 9      | 1992  | [39]       |
| NCI-H720    | L        | atypical carcinoid | 13     | 1992  | [39,40]    |
| NCI-H727    | L        | bronchial carcinoid | 23    | 1992  | [39]       |
| COR-L103    | L        | SCLC               | 3      | 1992  | [41]       |
| COR-L266    | L        | SCLC               | 1      | 1992  | [41]       |
| COR-L279    | L        | SCLC               | 12     | 1992  | [41]       |
| NCI-H82     | L        | SCLC               | 40     | 1996  | [42]       |
| NCI-H0446   | L        | SCLC               | 33     | 1996  | [42]       |
Table 1. Cont.

| Cell Line   | Source | Type              | # Refs | Year | References |
|-------------|--------|-------------------|--------|------|------------|
| NCI-H1930   | L      | SCLC              | 12     | 1996 | [42]       |
| NCI-H0510   | L      | SCLC              | 23     | 1996 | [42]       |
| NCI-H0524   | L      | SCLC              | 25     | 1996 | [42]       |
| NCI-H1105   | L      | SCLC              | 10     | 1996 | [42]       |
| NCI-H1436   | L      | SCLC              | 12     | 1996 | [42]       |
| NCI-H1694   | L      | SCLC              | 15     | 1996 | [42]       |
| NCI-H1963   | L      | SCLC              | 17     | 1996 | [42]       |
| NCI-H2029   | L      | SCLC              | 11     | 1996 | [42]       |
| NCI-H2171   | L      | SCLC              | 26     | 1996 | [42]       |
| NCI-H2196   | L      | SCLC              | 10     | 1996 | [42]       |
| HCC33       | L      | SCLC              | 15     | 1998 | [43]       |
| SCLC-J1     | L      | SCLC              | -      | 2018 | [43]       |
| QGP1        | Pa     | delta-islet carcinoma | 22 | 1980 | [45] |
| CM          | Pa     | insulinoma        | 5      | 1987 | [46]       |
| BON1        | Pa     | carcinoid LN met  | 12     | 1991 | [47]       |
| HuNET       | Pa     | VIP-secreting     | 2      | 2001 | [48]       |
| A99         | Pa     | small cell carcinoma | 3  | 2011 | [49]       |
| APL1        | Pa     | pancreatic liver met | -  | 2016 | [50]       |
| NT-3        | Pa     | WD carcinoid LN met | 2  | 2018 | [51]       |
| NT-18P      | Pa     | NET               | -      | 2022 | [52]       |
| NT-18LM     | Pa     | liver met NT-18P  | -      | 2022 | [52]       |
| NT-36       | Pa     | recurrence of NT-18P | -   | 2022 | [52]       |
| NT-32       | Pa     | pancreatic NEC    | -      | 2022 | [52]       |
| LnCaP       | Pr     | -                 | -      | 1989 | [53]       |
| NCI-H660    | Pr     | small cell prostate cancer | 15 | 1989 | [54] |
| Faugeroux 2020 | Pr | treatment-induced | - | 2020 | [55] |
| KUCApf13    | Pr     | treatment-induced | -     | 2021 | [56]       |
| N-TAK-1     | R      | rectal carcinoma  | -      | 1999 | [57]       |
| NECS-P      | R      | rectal carcinoma  | 1      | 2000 | [58]       |
| NECS-L      | R      | rectal carcinoma liver met | 1 | 2000 | [58] |
| KRJ-I       | SB     | ileal carcinoid   | 8      | 1996 | [59]       |
| CT-nu-1     | SB     | atypical duodenal carcinoid | - | 1998 | [60] |
| GOT1        | SB     | ileal carcinoid liver met | 3 | 2001 | [61] |
| CNDT2       | SB     | midgut carcinoid liver met | 3 | 2007 | [62] |
| P-STS       | SB     | ileal carcinoid primary | 4 | 2009 | [63] |
| L-STS       | SB     | ileal carcinoid LN met | 4 | 2009 | [63] |
| H-STS       | SB     | ileal carcinoid liver met | 3 | 2009 | [63] |
| TCC-NECT-2  | SB     | duodenal carcinoma | 2      | 2018 | [64]       |
| NT-38       | SB     | duodenal NEC      | -      | 2022 | [52]       |
| MTC-F       | T      | MTC               | 2      | 1990 | [65]       |
Table 1. Cont.

| Cell Line | Source 1 | Type | # Refs | Year | References |
|-----------|----------|------|--------|------|------------|
| MTC-SK    | T        | MTC  | 6      | 1990 | [65]       |

1 Adrenal medulla (AM), anus (An), Ampullary (AP), colon (C), carotid body (CB), esophagus (E), gastrointestinal junction (GEJ), jugulotympanic (JT), lung (L), pancreas (Pa), pituitary (Pi), prostate (Pr), rectum (R), small bowel (SB), stomach (St), thyroid (T), unknown (U).

2.1.1. NEN Cell Lines

Most NEN cell lines are derived from poorly differentiated carcinomas, whose aggressive behavior and rapid replication is better suited to long term in vitro culture than slow-growing well-differentiated NETs [66]. This unfortunately means that there is a lack of models for the latter types of tumors, although establishment of the first well-differentiated small bowel NET cell line (GOT1) and pancreatic NET cell line (NT-3) were reported [51,61]. Existing GEP-NET lines like CM, BON1, and KRJ-I exhibit significant karyotypic and genetic differences from most NETs, and may not be derived from enterochromaffin cells (although they may still have significant value as NEC models) [67–70].

Many NEN cell lines established in the late 20th century were derived from thyroid or lung primaries, and since then those developed have been from GEP-NETs. While development of new SCLC lines has continued [44], declining interest in such models reflects both decreasing smoking rates (and SCLC incidence) and increasing understanding of the limitations of 2D cell culture as a model system [35]. Increasingly, protocols for maintaining in vitro cell line models are established in parallel with PDX models of the same cells, a promising trend towards diversifying neuroendocrine research. Such combined models allow for assessment of multiple factors. For example, the first duodenal NEC cell line (TCC-NECT-2, 2018) induced cachexia in a PDX mouse model by an unknown mechanism, which invites further study that may have been missed if it had only been used in vitro [64,71]. Increasing accessibility of 3D culture techniques such as spheroids or organoids may also contribute to improved ability to recapitulate NEN characteristics.

The recently established SS-2 line showed greater expression of cancer stem cell markers in spheroids than in adherent conditions [28]. Debate over the validity of data based on cell lines affirms their role as part of a complementary set of different models, which are critical to piecing together the molecular mechanisms of NEN, but best used in combination with other models [18].

While many lines have been derived and immortalized from NEN, few of them continue to behave like NEN in standard tissue culture. Many cell lines derived from functional NENs rapidly lose secretory function in vitro [48]. Some existing cell lines have been discovered upon closer examination to actually be Epstein-Barr virus-transformed lymphoblastoid cells (L-STS, H-STS, KRJ-I) [72]. However, it remains unclear what qualities are best used to describe NEN cells—between genetics, function, and RNA-seq identified behavior [73]. For example, transcriptomic and secretomic comparison of BON1 and KRJ-I suggests that the latter line is phenotypically more neuroendocrine, while immunohistochemical comparison suggests the latter is actually of lymphoblastoid origin [70,72]. Contradictory results like these show that while the development of new cell lines and models for neuroendocrine research is exciting, it is also important to better investigate the validity of existing models and the research based on them.

2.1.2. NEPC Cell Lines

The rising prevalence of neuroendocrine prostate cancer (NEPC) is generally thought to be due to use of androgen receptor (AR) signaling inhibitors in treatment of prostate adenocarcinoma [14]. In vitro, many methods have been established for reliable transdifferentiation from adenocarcinoma into neuroendocrine phenotypes [74–76]. This review does not go into great detail about prostate adenocarcinoma cell lines which may be transdifferentiated as opposed to established NEPC lines.
2.1.3. PPGL Cell Lines

Pheochromocytomas (PCC, referred to in combination with paragangliomas as PPGL) have historically proven challenging to establish as cell lines. The first human pheochromocytoma cell lines, KNA and KAT45, were reported in 1998 [19,20]. No further pheochromocytoma models were developed until 2013, when a slow-growing, benign tumor was successfully immortalized via lentiviral infection with human telomerase reverse transcriptase, producing the hPheo1 cell line [21]. While this method may affect the behavior of the underlying cells, it shows potential for allowing research into the mechanisms of such slow-growing tumors that typically struggle in vitro, and has been reproduced with other pheochromocytomas [77]. Murine models of PPGL such as MTT and MPC have also proven valuable since human cell lines are so sparse [78].

2.2. 3D Models

Organoid, tumoroid, and other 3D tissue culture strategies recapitulate the tumor microenvironment to a greater degree than ordinary cell culture at the cost of added expense and complexity per sample. Increasingly, automation and standardized, well-characterized protocols for organoid establishment have allowed a greater degree of tumor types to be captured in organoid lines and used for research [79]. While traditional cell lines remain the simplest and most commonly used model, organoids are a valuable step up that can help to characterize especially more indolent tumor types that struggle to grow in conventional tissue culture. Organoid systems are presented in Table 2.

Table 2. Human neuroendocrine neoplasm-derived organoids.

| PDX Line     | Host | Source 1 | Successes 2 | Attempts 2 | Year | References |
|--------------|------|----------|-------------|------------|------|------------|
| NEC913, NEC1452 | spheroid | AP, C   | 1           | 1           | 2019 | [23]       |
| CRC14       | organoid | C       | 1           | 1           | 2016 | [80]       |
| Kawasaki 2020 | organoid | GEP-NEC | 16          | 23          | 2020 | [79]       |
| Kawasaki 2020 | organoid | GEP-NET | 3           | 16          | 2020 | [79]       |
| Kim 2019    | organoid | L       | 3           | 3           | 2019 | [81]       |
| Gmeiner 2020 | organoid | L       | 4           | 4           | 2020 | [82]       |
| April-Monn 2021 | organoid | Pa   | 6           | 7           | 2021 | [66]       |
| MSK-PCA4    | organoid | Pr      | 7           | 32          | 2014 | [83]       |
| OWCM        | organoid | Pr      | 4           | 25          | 2018 | [84–86]    |
| CRC19       | organoid | R       | 1           | 1           | 2016 | [80]       |
| Dijkstra 2021 | organoid | St/C  | 1           | 3           | 2021 | [87]       |
| ANI-275     | spheroid | U       | 1           | 1           | 2017 | [88]       |

1 Adrenal medulla (AM), anus (An), Ampullary (AP), colon (C), carotid body (CB), esophagus (E), gastroesophageal junction (GEJ), jugulotympanic (JT), lung (L), pancreas (Pa), pituitary (P), prostate (Pr), rectum (R), small bowel (SB), stomach (St), thyroid (T), unknown (U). 2 “Successes” denotes models established for serial passaging, and “attempts” denotes number of tumor explants which failed to survive (to the extent reported on by the primary article in question).

2.2.1. NEN 3D Models

Individually developed 3D models are valuable for understanding which parameters affect samples’ ability to survive as organoids. Recent models in particular have focused on directly transitioning patient tissue into 3D growth environments to better recapitulate the tumor sources [87]. Library and biobank projects that standardize collection and seeding procedures across multiple centers have also contributed greatly to the number of different models available [79]. In particular, Fuji et al.’s recent work comparing the growth of each tissue sample across a matrix of different media supplements provides greater context...
to the different possible neuroendocrine niches [80]. As more NEN organoid models are developed, the heterogeneity and different growth factors needed by different tumors types will be further elucidated—in particular, currently the vast majority of NET (as opposed to NEC) cells fail in vitro, and developing models which provide them a suitable niche for growth should be a priority in the near future [80,89]. Recent advances have also been made in generation of small cell lung cancer (SCLC) organoids and a single lung-derived non-small cell neuroendocrine carcinoma [81,82].

2.2.2. NEPC 3D Models

Neuroendocrine prostate cancer organoids were first reported in 2018, in 3D culture using Matrigel [84]. The same organoids were also reimplanted as patient-derived organoid xenografts (PDOXs) [85]. Projects spanning in vitro and in vivo techniques like this by using PDOXs in conjunction with the original organoids help to find more reliable results from multiple convergent types of evidence. Follow-up studies have developed a defined medium for use in 3D culture based on functionalized polyethylene glycol hydrogel [86]. Defined media presents an opportunity to better understand the different niches in which different subtypes of tumor may flourish. Data transparency is particularly helpful in such projects—reporting not only which defined media mixtures worked but also all options which were tested [79,80].

PDOXs and seeding of PDX tissue into organoid culture allows a certain degree of interchange between these types of models, although it is unclear to what extent characteristics of the tumors are preserved during such changes. One advantage that organoids have over PDXs is the use of automation and robotics to achieve high throughput. One recent study derived organoids from the MURAL prostate cancer PDX biobank to compare many organoids in parallel, at scales which would be impossible in vivo [90].

2.2.3. PPGL 3D Models

There are no published manuscripts on PPGL 3D models [91–93].

2.3. Patient-Derived Xenografts

Many of the previously discussed models have been used successfully in xenografts after some in vitro passaging (which has been discussed elsewhere in detail for GEP-NENS), but xenografts of samples acquired directly from biopsy or surgery into immunodeficient mice is typically seen as the gold standard of comparative evidence [18,94]. Patient derived xenografts are presented in Table 3.

Table 3. Neuroendocrine neoplasm patient-derived xenografts.

| PDX Line | Host Source 1 | Successes 2 | Attempts 2 | Year | References |
|----------|---------------|-------------|------------|------|------------|
| SJ-ACC3  | CB17 scid\(^{−/−}\) | AC          | 1          | 1    | 2013 [95]  |
| HROC57  | NMRI nu/nu mice | C           | 1          | 1    | 2018 [27]  |
| TEG13    | athymic nude mice | E           | 1          | 1    | 1995 [96]  |
| Kawasaki 2020 | NOG mice | GEP-NEC    | 15         | 22   | 2020 [79]  |
| Tran 2022 | NSG mice     | GEP-NEC    | 2          | 6    | 2022 [97]  |
| Yang 2016 | NOD/SCID mice | GEP-NET    | 106        | 6    | 2016 [98]  |
| Gaudenzi 2017 | Tg(fli1a:EGFP) y1 zebrafish | GEP-NET | 2          | 3    | 2017 [99]  |
| Anderson 2015 | NOD/SCID mice | L          | 8          | 12   | 2015 [100] |
| LXFS     | NOG Taconic mice | L          | 1          | 1    | 2021 [101] |
| HNV PDX-PNET | athymic nude mice | Pa        | 1          | 1    | 2018 [102] |
| Gaudenzi 2017 | Tg(fli1a:EGFP) y1 zebrafish | Pi        | 1          | 6    | 2017 [99]  |
### Table 3. Cont.

| PDX Line      | Host                  | Source 1 | Successes 2 | Attempts 2 | Year   | References       |
|---------------|-----------------------|----------|-------------|------------|--------|------------------|
| Powers 2017   | NSG mice              | PPGL     | 3           | 13         | 2017   | [105]            |
| UCRU-PR-2     | nude mice             | Pr       | 1           | 1          | 1987   | [104–106]        |
| WISH-PC2      | SCID mice             | Pr       | 1           | 1          | 2000   | [107,108]        |
| WM-4A         | SCID mice             | Pr       | 1           | 1          | 2008   | [108]            |
| MDA PCa       | CB17 SCID mice        | Pr       | 5           | 11         | 2011   | [16,109,110]     |
| KUCaP13       | SCID mice             | Pr       | 1           | 1          | 2014   | [56]             |
| LTL           | NOD/SCID mice         | Pr       | 7           | 18         | 2014   | [111]            |
| LuCaP         | Nu/Nu or CB17 SCID mice| Pr   | 4          | 2          | 2017   | [112]            |
| MURAL         | NSG or NOD/SCID mice  | Pr       | 30          | 2          | 2018   | [113,114]        |
| Faugeroux 2020| NSG mice              | Pr       | 7           | 15         | 2020   | [55]             |
| EN-1          | nude mice             | SB       | 1           | 1          | 1998   | [60]             |
| TSG15         | athymic nude mice     | St       | 1           | 1          | 1995   | [96]             |
| HuPrime GA    | Balb/c nude mice      | St       | 20          | 2          | 2013   | [115,116]        |

1 Adrenal medulla (AM), anus (An), colon (C), canid body (CB), esophagus (E), gallbladder (G), gastroesophageal junction (GEJ), jugulotympanic (JT), lung (L), pancreas (Pa), pituitary (Pi), prostate (Pr), rectum (R), small bowel (SB), stomach (St), thyroid (T), unknown (U). 2 Fraction of attempts which were NE not specified. 2 "Successes" denotes models established for serial passaging, and "attempts" denotes number of tumor explants which failed to survive (to the extent reported on by the primary article in question).

#### 2.3.1. NEN PDXs

Although the first NEN PDX models (TEG13 and TSG13) were established in 1995, there was relatively little development in this area for the following two decades [96]. Compared to prostate cancers, where biobanks increasingly standardize protocols and collection procedures across regions, new NEN PDXs have been developed incrementally and by disparate methods [99,100,102,116,117]. Recently, 2 GEP-NEC PDX models have been described by Tran et al. [97]. Beyond drug screening, some NEN PDXs have also been used to analyze circulating cancer cells [116]. Since zebrafish mature more rapidly than mice but conserve many aspects of mammalian vasculature, there has recently been increased interest in their use as a model for angiogenesis in NEN development and invasion [99]. One organoid NEN biobank has also developed companion PDXs for their models, covered in more detail in that section [79]. To date, no studies have successfully established well-differentiated NENs in PDX lines.

#### 2.3.2. NEPC PDXs

Historically, limited models for neuroendocrine prostate cancer (NEPC) specifically have been developed. With the advent of biobanks operating on standardized protocols, increasing numbers of NEPC models have become available [111–113]. Many prostate adenocarcinomas have been observed to transdifferentiate to a neuroendocrine phenotype under androgen starvation [111]. Of particular interest, Faugeroux et al. showed that circulating tumor cell explants from non-NE primaries may develop into NE tumors [55].

#### 2.3.3. PPGL PDXs

One successful set of PPGL PDXs has been generated, although via a technically complex protocol [103]. Recent progress also includes a high-fidelity SDHb<sup>-/-</sup> rat-to-mouse xenograft [93].

#### 2.4. Genetically-Engineered Mouse Models

Neuroendocrine tumors are some of the most frequently inherited types of cancer, and are associated with more than ten different genetic syndromes [118]. These range...
from general oncogene/tumor suppressor genes like TP53 or RB1 to ones associated with systemic neuroendocrine disease like MEN1, VHL, or NF1 to highly specific risk factors like SDHx and EPAS1.

While cell lines and organoid models can be highly valuable in studying treatment and improving understanding of disease states, genetically engineered mouse models provide a window into tumorigenesis itself, in particular from a genetic perspective [119]. Early models often focused on systemic knockouts or transgenes, but engineered systems with such features as Cre/lox recombinases or drug-inducible promoters allow for precise spatial and temporal control of models [120]. These tools are especially useful with regard to genes that have large systemic effects like TP53, allowing researchers to isolate changes to it to a particular location or organ [121]. Similarly, while mouse models of heritable neuroendocrine disorders are valuable in recapitulating the overall progression of the disease, more specific models help to refine understanding of highly complex disorders [121,122]. MEN1 mutations are most often associated with pancreatic, parathyroid, and pituitary tumors [123]. MEN2-associated (RET) mutations are most often associated with medullary thyroid carcinoma, pheochromocytoma, and parathyroid tumors [124]. NF1 mutations are most often associated with adrenal, gastroenteropancreatic, and parathyroid tumors [125].

In the following section, we focus specifically on models engineered in mice. Notable genetic NEN models have also been developed in other organisms, in particular zebrafish. These are not discussed below for brevity but are referenced here for completeness [126–136].

2.4.1. NEN GEMMS

Specific models of NEN subtypes are lacking since many NENs are interrelated or poorly understood in terms of molecular drivers [122,137]. Use of organ-specific Cre/lox and drug-induced systems has been critical in developing more specific NEN models, although most today still focus on pancreatic NETs [120]. Many models also link SV40-Tag oncogenes to particular promoters to facilitate local expression. For pancreatic NETs the RIP-Tag paradigm and its successors have been especially well-studied [138–140]. Gastric NET models have been developed that induce tumorigenesis through both overexpression and inhibition of gastrin-related genes [141,142]. There is a distinct lack of specific GEMMs for intestinal NETs (even though they are among the most prevalent GEP-NETs) [122]. Current models are based on SV40-Tag driven by glucagon or intestinal trefoil factor promoters [143,144]. As lung tumors are rarely resected, GEMMs are an essential tool in lung NEN research [122,145]. Many current lung NEC models focus on selective knockouts of TP53, RB1, or PTEN to recapitulate SCLC or LCNEC [146,147]. Genetically engineered mouse models are presented in Table 4.

Table 4. Genetically-engineered mouse models of neuroendocrine neoplasia.

| Model 1 | Organ 2 | Neoplasia Type | Model Type 3 | Gene (Promoter 4) | Year | References |
|---------|---------|----------------|--------------|-------------------|------|------------|
| EPAS1   | -       | polyhormonal, polycythemia | transgenic  | EPAS1A529V       | 2019 | [148]      |
| NH1−/−  | AM      | PCC, leukemia   | heterozygous KO | NF1              | 1994 | [149]      |
| NF1+/−  | AM      | pheo            | heterozygous KO | NF1              | 2016 | [92]       |
| NES-VHL | AM      | PGL             | TS inducible KO | VHL (NES)       | 2017 | [150]      |
| SDHBf/f NF1+/− Rosa/mg/+/Th-Cre | AM | PCC | multiple KO | SDHB, NF1 | 2021 | [151] |
| Inka Arf+/+ Pten+/− | AM, C, L | PCC, NEC, NEPC | multiple KO | CDKN2A, ARF, PTEN | 2002 | [152] |
| Inka Arf+/− Pten+/− | AM, C, L | PCC, NEC, NEPC | multiple KO | CDKN2A, ARF, PTEN | 2002 | [152] |
| RET-KO | AM, T   | PCC, MTC       | KI           | RET              | 2000 | [153]      |
| ITF-Tag | C       | NEC             | transgenic   | SV40-Tag (ITF)   | 2004 | [144]      |
| Model 1 | Organ 2 | Neoplasia Type | Model Type 3 | Gene (Promoter 4) | Year | References |
|---------|---------|----------------|--------------|------------------|------|------------|
| CC10-hASH1 | L         | SCLC, NSCLC | transgenic | ASCL1 (SCGB1A1) | 2000 | [154] |
| RB-TP53-KO | L         | SCLC, LCNEC | homozygous KO | RB1, TP53 | 2003 | [155] |
| RB-TP53-RB1-KO | L         | SCLC, LCNEC | homozygous KO | RB1, TP53, RB1 | 2010 | [156] |
| RP-TP53-PTEN-KO | L         | SCLC, LCNEC, NSCLC | multiple KO | RB1, TP53, PTEN | 2014 | [146] |
| RIP-Tag | Pa | NET | transgenic | SV40-Tag (RIP2) | 1985 | [157] |
| RIP-Tag2 (Tg(RIP1-Tag)2Dh) | Pa | NEN various | transgenic | SV40-Tag (RIP) | 1985,143,157,158 | |
| VT-C (Avp-Tag) | Pa | insulinoma | transgenic | SV40-Tag (AVP) | 1987 | [159] |
| L-PK/Tag (Tg(Pklr-Tag)Ak) | Pa | insulinoma, D cell hyperplasia | transgenic | SV40-Tag (L-type pyruvate kinase) | 1992 | [162] |
| GP1.5 Tag, GP10.5 Tag | Pa | insulinoma, ductal hyperplasia | transgenic | SV40-Tag (GAST) | 1993 | [163] |
| RIP-Tag5 (Tg(RIP1-Tag)5Dh) | Pa | insulinoma/invasive carcinoma | transgenic | SV40-Tag (RIP) | 1996 | [164] |
| RIP-MyrAkt1 | Pa | NET | transgenic | MyrAkt1 (RIP) | 2001 | [165,166] |
| Cdk4R24C/R24C (Cd4tm1.1Bbd/Cd4tm1.1Bbd) | Pa | insulinoma | homozygous KO | CDK4R24C | 2001 | [167] |
| pIns-c-MycERTAM/RIP-Bcl-xL | Pa | islet cell carcinoma | TS transgenic | MYC, BCL-xl (RIP) | 2002 | [168] |
| Men1T+/Men1T/+ (Men1tm1Zqw/Men1+) | Pa | polyhormonal | heterozygous KO | MEN1 | 2003 | [169] |
| Men1P1/−RipCre+ (Men1tm1Zqw/Men1tm1.2Zqw Tg(Ins2-cre)23Herr/0) | Pa | islet cell carcinoma | homozygous KO | MEN1 (RIP) | 2003 | [169,170] |
| Gcgr−/− | Pa | glucagonoma, exocrine hyperplasia | homozygous KO | GCGR | 2003 | [171] |
| elastase-tv-a; RCAS-c-myc; p16/p19+/− | Pa | NET | transgenic | MYC, INK4a/ARF (EL) | 2003 | [172] |
| elastase-tv-a; RCAS-PyMT; p16/p19+/− | Pa | progenitor | transgenic | pyMT, INK4a/ARF (EL) | 2003 | [172] |
| Prdx1−/− (Prdx1tm1Rave/Prdx1tm1Rave) | Pa | adenoma | homozygous KO | PRDX1 | 2003 | [173] |
| Men1tm1Gfk/Rip-cre+ (Men1tm1Gfk/Men1tm1Gfk Tg(Ins2cre25Mgn)) | Pa | insulinoma | TS homozygous KO | MEN1 (RIP) | 2004 | [174] |
| Men1tm1Gfk/Rip-cre+; Rb1tm1Bj (Men1tm1Gfk/Men1tm1Gfk Tg(Ins2cre25Mgn)) | Pa | insulinoma | heterozygous KO | MEN1 | 2007 | [175] |
| RIP-MyrAkt1 (Tg(Ins2-Akt1*)3Mbb) | Pa | islet cell carcinoma | transgenic | AKT1 (RIP) | 2008 | [166] |
| Men1tm1Cre/+ | Pa | insulinoma | heterozygous KO | MEN1 | 2009 | [176,177] |
| Pdx1-Cre; Men1tm1+/− (Men1tm1Cre/+Men1tm1Cre; Tg(Pdx1-cre)89.1Dam/0) | Pa | insulinoma | homozygous KO | MEN1 (PDX1) | 2009 | [178] |
| Pdx1-Cre; Vhl−/− (Vhltm1Izsa/Vhltm1Izsa Tg(Pdx1-cre)89.1Dam/0) | Pa | adenoma | TS homozygous KO | VHL (PDX1) | 2009 | [179] |
| Men1F/−-GlucCre+ | Pa | mixed | TS homozygous KO | MEN1 (RG) | 2010 | [180] |
Table 4. Cont.

| Model 1 | Organ 2 | Neoplasia Type | Model Type 3 | Gene (Promoter 4) | Year | References |
|---------|---------|----------------|--------------|-------------------|------|------------|
| Glu-Cre;Men1^L/L | Pa | insulinoma | TS homozygous KO | MEN1 (RG) | 2010 | [181] |
| RipTag-IREs-Luciferase (Rtl1) (Tg(Ins1-Tag, -luc)1Gcr) | Pa | insulinoma/invasive carcinoma | transgenic | SV40-Tag (RIP) | 2010 | [136] |
| RIP-Tag (Tg(RIP1-Tag2DH)) | Pa | insulinoma/invasive carcinoma | transgenic | SV40-Tag (RIP) | 2010 | [140] |
| Gcgr^+/- (Gcgr^tm1Jcp/Gcgr^tm1Jcp) | Pa | glucagonoma | homozygous KO | GCG | 2011 | [182] |
| Cub^tm1.2Yx1/Cub^+ | Pa | insulinoma | heterozygous KO | CUL9 | 2011 | [183] |
| PDX1-MEN | Pa | NET | TS homozygous KO | MEN1 (PDX1) | 2012 | [184] |
| Rip-TbAg (Tg(2-Tag*, FLPe)#Gne) | Pa | insulinoma/invasive carcinoma | transgenic | SV40-Tag (RIP) | 2012 | [185] |
| Pc2^+/-(Pcsk2^tm1Dfs/Pcsk2^tm1Dfs) | Pa | adenoma | homozygous KO | PCSK2 | 2014 | [186] |
| RenCre; Tp53^loxP/loxP; Rb^loxP/loxP | Pa | glucagonoma, unrelated sarcoma | TS homozygous KO | TP53, RB1 (REN) | 2014 | [187] |
| Gcg^+/- | Pa | islet cell carcinoma | multiple KO | GCG | 2015 | [188] |
| Fabpl-Cre^+/Rb^+//(Tg(Fabp1-cre)1Jig/Rb^+/) | Pa | NEC | TS homozygous KO | RB1 (FABP1) | 2015 | [189] |
| RIP7-rTA; tet-o-MT; p48-Cre; p16^+/p16^loxP/loxP | Pa | NET | transgenic | PyMT, INK4A/ARF (RIP, PTF1A) | 2016 | [190] |
| Pdx1-tTA; tet-o-MT; p48-Cre; p16^+/p16^loxP/loxP | Pa | NET | transgenic | PyMT, p53 (PDX1, PTF1A) | 2016 | [190] |
| Men1^L/L; RIP2-CreER (Tg(Ins2-cre/ERT)1Dam/J, (RIP2-CreER)), Men1^tm1.1Ctre/J | Pa | insulinoma | TS inducible KO | MEN1 (RIP2) | 2017 | [120] |
| RIP-Tag (Tg(RIP1-Tag2DH)) | Pa | pNET nonfunctional | transgenic | SV40-Tag (RIP) | 2019 | [139] |
| MipCre;Men1^tm1.2Ctre, Pten^tm1Hwu, Ins1^tm1.1(cre)Thor | Pa | insulinoma | TS homozygous KO | MEN1, PTEN (RIP) | 2020 | [191] |
| Pdx1-Cre; Rb^+/ | Pa | NET | TS homozygous KO | RB1 (PDX1) | 2020 | [192] |
| INS-p25OE | Pa | NET | TS inducible KI | CDK5R1 (IN2/tetOp) | 2021 | [193] |
| Glu2-Tag | Pa, C | NET | transgenic | SV40-Tag (RG) | 1988 | [194] |
| RIP-Tag/RIPPyST1 | Pa, C | NET | transgenic | SV40-Tag (RIPPyST1) | 1991 | [143] |
| GLUTag-Y Tg(Gcg-TAg)25Ddr | Pa, C | invasive carcinoma, glucagonoma | transgenic | SV40-Tag (RG) | 1992 | [195,196] |
| Model | Organ | Neoplasia Type | Model Type | Gene (Promoter) | Year | References |
|-------|-------|----------------|------------|----------------|------|------------|
| TP53+/-; RB+/- | Pa, Pi, T | MTC, ICC, lymphoma | multiple KO | TP53, RB1 | 1994 | [197] |
| MEN1+/− | Pa, Pi, T, PT, AM | NET | heterozygous KO | MEN1 | 2011 | [198] |
| RIP-Tag/RIPPyST | Pa, SB | polyhormonal invasive carcinoma | transgenic | SV40-Tag, PyST1 (RIP) | 1990 | [156] |
| Secretin-Tag | Pa, SB, C | polyhormonal NEN | transgenic | SV40-Tag (SCT) | 1995 | [200] |
| GHRH-MT | Pi | polyhormonal | transgenic | GHRH (MT) | 1992 | [201] |
| AVP/SV40 | Pi | polyhormonal | transgenic | SV40 (AVP) | 1992 | [202] |
| CRH-MT | Pi | corticotropinoma | transgenic | CRH (MT) | 1992 | [203] |
| PyLT-1 | Pi | corticotropinoma | transgenic | PyLT (Py early region) | 1992 | [204] |
| Secretin-Tag | Pa, SB, C | polyhormonal NEN | transgenic | SV40-Tag (SCT) | 1995 | [200] |
| RIP-Tag (Tg(RIP1-Tag)2Dh) | Pa, SB | pNET and siNET | transgenic | SV40-Tag (RIP) | 2020 | [199] |
| Secretin-Tag | Pa, SB, C | polyhormonal NEN | transgenic | SV40-Tag (SCT) | 1995 | [200] |
| GHRH-MT | Pi | polyhormonal | transgenic | GHRH (MT) | 1992 | [201] |
| AVP/SV40 | Pi | polyhormonal | transgenic | SV40 (AVP) | 1992 | [202] |
| CRH-MT | Pi | corticotropinoma | transgenic | CRH (MT) | 1992 | [203] |
| PyLT-1 | Pi | corticotropinoma | transgenic | PyLT (Py early region) | 1992 | [204] |
| POMC-SV40 | Pi | corticotropinoma | transgenic | PyLT (POMC) | 1993 | [205] |
| Cdkn1b+/− | Pi | somatotropinoma | heterozygous KO | CDKN1B | 1996 | [206–208] |
| p18INK4c | Pi | somatotropinoma | heterozygous KO | CDKN2C | 1998 | [209] |
| p18−/−; p27−/− | Pi | corticotropinoma | homozygous KO | CDKN2C | 1998 | [209] |
| hFSHB-SV40tsTag | Pi | gonadotropinoma | non-functioning adenomas | SV40-Tag (FSHB) | 1998 | [210] |
| Rb−/−; ARF−/− | Pi | - | heterozygous KO | RB1, ARF | 2002 | [217] |
| Men1TSM/− | Pi | prolactinoma | multiple KO | MEN1 | 2001 | [213,214] |
| HMGa2 | Pi | polyhormonal | transgenic | HMGa2 (CMV) | 2002 | [215] |
| p18/aSU | Pi | thyrotropinoma | multiple KO | TP18, aSU | 2002 | [216] |
| Rb−/−; ARF−/− | Pi | - | heterozygous KO | RB1, ARF | 2002 | [217] |
| Men1AN/AN; RIPcre(Men1tm1.2Ctre/Ins2-cre)25Mgn/0 Tg(Ins2-cre)1Heed/0 Tg(Ins2-cre)1Dh/0 | Pi | insulinoma | TS homozygous KO | MEN1 (RIP) | 2003 | [218] |
| Ink4c/p53-null | Pi | - | homozygous KO | INK4c, ARF | 2003 | [219] |
| HMGa1 | Pi | polyhormonal | transgenic | HMGa1 (CMV) | 2005 | [220] |
| aCSU PTG Rh−/− | Pi | gonadotropinoma | transgenic | PTG (aSU), RB1 | 2005 | [221–222] |
| Cdk4R/R; p27−/− | Pi | - | homozygous KO | CDK4R/R CDKN1B | 2005 | [224] |
| Rb−/−; In1−/− | Pi | corticotropinoma | heterozygous KO | Rb1, IN1 | 2006 | [225] |
| Prkar1a−/− | Pi | somatotropinoma | TS heterozygous KO | PRKAR1c | 2008 | [226] |
| Aip−/− | Pi | somatotropinoma | heterozygous KO | AIP | 2010 | [227] |
| Tg-PCE; p27Kip1−/− | Pi | somatotropinoma | transgenic | CCNE1 CDKN1B | 2010 | [228] |
| p19Ink4d | Pi | polyhormonal | homozygous KO | CDKN2D | 2014 | [229] |
| Crh-1201 | Pi | corticotropinoma | inducible KI | CRH (mutCrh) | 2014 | [230] |
| Rh−/−; Tp53−/− | Pi, T, Pa | MTC, ICC | multiple KO | TP53, RB1 | 1995 | [231] |
| TRAMP | Pr | NEPC, NEC | transgenic | SV40-Tag (PB) | 1995 | [232–234] |
| CR2-Tag | Pr | NEPC, NEC | transgenic | SV40-Tag (Cryptdin-2) | 1998 | [235] |
| Model 1 | Organ 2 | Neoplasia Type | Model Type 3 | Gene (Promoter 4) | Year | References |
|---------|---------|----------------|--------------|-----------------|------|------------|
| PSP-TGMAP | Pr | NEPC, NEC | transgenic | SV40-Tag (PSP94) | 2002 | [236,237] |
| 12T-7f LPB-Tag/PB-Hepsin | Pr | NEPC | transgenic | SV40-Tag (PB) | 2004 | [236] |
| PSP-KIMAP | Pr | NEPC | KI | SV40-Tag (PSP94) | 2005 | [237,239] |
| PS3PE-/-/-; RbPE-/-/- | Pr | NEPC, adenoma | homozygous KO | TP53, R11 | 2006 | [240] |
| FG-Tag | Pr, AC | NEPC, ACT | transgenic | SV40-Tag (HbF) | 1996 | [241–243] |
| PTH-MEN | PT | - | TS homozygous KO | MEN1 (PTH) | 2003 | [244] |
| Vil-Cre-ERT2 LoxP-Tag (Tg(Vil-cre) 997Gum/J) | SB, C | NEC, glandular, mixed | transgenic | SV40-Tag (stochastic) | 2010 | [245] |
| INS-GAS | St | NET | transgenic | GAST (RIP) | 1993 | [141] |
| bK6-HPV16e | St | NEC | transgenic | HPV-16 early region (b66) | 1994 | [246] |
| Gastrin KO | St | NET | homozygous KO | GAST | 1998 | [142] |
| Atp4b-SV40 Tag | St | NEC | transgenic | SV40-Tag (Atp4b) | 2004 | [247] |
| Villin-Cre; Men13loxP/loxP | St | adenoma | TS homozygous KO | MEN1 (Villi) | 2012 | [248] |
| CEA424-SV40-Tag (Tg(CEACAMS-Tag) LS496Wzm/Cnrm) | St | dysplastic, NEC | transgenic | SV40-Tag (CEA) | 2012 | [249] |
| Atp4cR103C/R103C | St | dysplasia | homozygous KO | ATP4A (R103C) | 2016 | [250] |
| VillinCre; Men1loxP/loxP; Sat-/-/- | St | ECL cell tumor | homozygous KO | MEN1 (Villi) | 2017 | [251] |
| CT/RET | T | MTC | transgenic | RETSMAR (Ctct/cgrp/CGRP) | 1997 | [252] |
| RET/PTC3 | T | PTC | TS KI | RET/ptc3 (TG) | 1998 | [253] |
| RET/PTC1 | T | PTC | TS KI | RET/ptc1 (TG) | 1999 | [254] |
| ret/PTC1 TP53+/− | T | ATC | multiple KO | RET-PTC1 (TG), TP53 | 2000 | [255] |
| CALC-MEN2B-RET | T | MTC | KI | RETM131ST (CT/CGRP) | 2000 | [256] |
| TRK-T1 | T | PTC | transgenic | TRK-T1 (TG) | 2000 | [257] |
| RET/PTC3, Tp53+/− | T | ATC | homozygous KO | RET-PTC3 (TG), TP53 | 2001 | [258] |
| TrRbPV-PV | T | FTC | multiple KI | TRPV/PV (Tg) | 2002 | [259] |
| Rap1bG12V-LoxP-N17 | T | FTC | transgenic | RAP1BG12V (TG) | 2004 | [260] |
| N-RASQ61K | T | PTC | transgenic | NRASQ61K (TG) | 2006 | [261] |
| CT-RET | T | MTC | transgenic | RET1 (CT/CGRP) | 2010 | [262] |
| Pten1/−/−;TPO-Cre | T | FTC | TS homozygous KO | PTEN (TPO) | 2010 | [263,264] |
| BRAFV600E | T | PTC | TS inducible KI | BRAFV600E (TG) | 2011 | [265] |
| Pten-PPFP | T | FTC | homozygous KO | PPFP, PTEN (TPO) | 2011 | [266] |
| [Pten, p53] thyr−/− | T | ATC | TS homozygous KO | TP53, PTEN | 2011 | [267] |
| R1a-TpoKO | T | FTC | TS homozygous KO | PRKAR1A (TPO) | 2012 | [268] |
| p25OE | T | MTC | TS inducible KI | CDK5R1 (ENOZ) | 2013 | [269] |
| ThrP/PV, KrasG12D | T | ATC | homozygous KI | THR/P/PV/TG (TG) KRA5G12D (TG) | 2014 | [270] |
Table 4. Cont.

| Model ¹ | Organ ² | Neoplasia Type | Model Type ³ | Gene (Promoter ⁴) | Year | References |
|---------|---------|----------------|--------------|-------------------|------|------------|
| BRAF<sup>V600E</sup>/PIK3CA<sup>H1047F</sup> | T | ATC | TS KI | BRAF<sup>V600E</sup> (TG) PIK3CA<sup>H1047R</sup> | 2014 | [271] |
| BRAF<sup>V600E</sup>/PIK3CA<sup>H1047F</sup> | T | ATC | TS KI | BRAF<sup>V600E</sup> (TPO) | 2014 | [147,272] |

¹ ?/? indicates that multiple homo/heterozygous knockout combinations were created targeting the same genes.
² Adrenal medulla (AM), anus (An), colon (C), carotid body (CB), esophagus (E), gastroesophageal junction (GEJ), jugulotympanic (JT), lung (L), pancreas (Pa), Pituitary (Pi), prostate (Pr), parathyroid (PT), rectum (R), small bowel (SB), stomach (St), thyroid (T), unknown (U).
³ Tissue specific (TS), knock-out (KO), knock-in (KI); multiple indicates both homozygous and heterozygous models were used.
⁴ Bovine arginine vasopressin (AVP), bovine thyroglobulin (Tg), carcinoembryonic antigen (CEA), mouse metallothionein 1 (MT), mouse insulin promoter (MIP), polyoma middle T antigen (CEA), mouse metallothionein 1 (MT), mouse insulin promoter (MIP), polyoma middle T antigen (Py-My), rat elastase promoter 1 (EL), rat glucagon promoter (RG), rat insulin promoter (RI), rat insulin-2 (RIP2), rat probasin promoter (PB), simian virus 40 large T antigen (SV40-Tag).

2.4.2. NEPC GEMMS

Before treatment-induced neuroendocrine transdifferentiation of prostate cancer was well understood, GEMMs that modeled transdifferentiation of prostate adenocarcinomas to NE phenotypes were seen as flawed, even though this has since been observed clinically [240,273]. As t-NEPC has become more common in recent years, there has been renewed interest in models that feature this neuroendocrine transdifferentiation [274,275]. Most models depend on oncogenes driven by variations of probasin or PSP94 promoters [232,236,239,241,276].

2.4.3. PPGL GEMMS

While models for genes of cluster 2 PPGL (RET, NF1, and TMEM127) have been studied since 1992, these models are suboptimal as they are generally associated with development of additional unrelated non-neuroendocrine tumors [92]. Historical attempts at generating GEMMS of cluster 1 pseudohypoxia (VHL, SDH) PPGL have failed to develop tumors or are embryonically lethal [277]. However, recent developments have changed this: The first successful pseudohypoxic PPGL GEMM was recently developed with a gain-of-function EPAS1 mutation, characterizing Pacak-Zhuang syndrome [148], and tetracycline-induced dual SDHB/NF1 mouse model was recently developed (showing that SDHB inactivation alone was insufficient for tumorigenesis, but coupling with NF1 leads to pheochromocytoma) [91,151].

3. Conclusions

NENs constitute a heterogeneous and complex set of diseases. This feature demands a similarly heterogeneous set of models to span the genetic and phenotypic diversity of the diseases. Since many forms are quite low in incidence, patient-derived models and clinical data about these diseases is at a premium, and preclinical models are all the more necessary to develop treatments for these patients with distinct but still lethal disease. Since aggressive disease is often better suited to in vitro growth and allows for more rapid assessment in mouse models, models are lacking for more indolent forms of neuroendocrine neoplasia, among all subtypes, but especially PPGL.

In this review, we have summarized available preclinical models for NENs, their history, as well as current use and translation. While no single model can fully recapitulate disease in the human body, convergent evidence from multiple different types of models brings us closer to that understanding. In spite of the many models developed, there is relatively little sharing and combination of those models for such integrated investigations. Future work would benefit from horizontal use of multiple types of models by researchers via increased collaborative sharing of data and models, including difficulties encountered during their generation. Large biobank projects are helpful in reaching a wide variety of a single type of model, but current biobanks have not made efforts to capture heterogeneity between model types as well as between individual models. Cell lines are perhaps the easiest models to work with for more aggressive disease types that grow well in simple...
in vitro culture, however, they may not reflect the actual phenotype of disease in vivo, and many patient-derived cells fail to thrive in continuous culture. Organoid or tumoroid models that better recapitulate the tumor microenvironment can allow for growth of a greater variety of tumor types in vitro, and better model their biology and responses to treatment. Immunodeficient PDX models further capture interactions between tumors and other tissues and in particular routes of metastasis. While immunocompetent mouse models are more complex and less often successful, they further allow for modeling tumor-immune interactions which are increasingly critical in understanding the potential of modern immunotherapy. Finally, genetically engineered mouse models fill a critical niche in understanding the pathogenesis of tumors, in particular in combination with spatial and temporal controls to introduce related mutations in a controlled fashion within mouse tissue.

Since neuroendocrine neoplasia represent such a genetically and phenotypically diverse group of pathologies, a diverse selection of models is also necessary to improve our understanding and treatment of them. This review underscores the conclusion that, despite persistent efforts by many groups, the establishment and application of NEN disease models have been limited. One reason is the indolent nature of these slowly growing tumors that make them difficult to propagate in culture or in animals, but another key factor is the rare nature of this disease and relatively small number of patients. Considering the recent rise in incidence (a 6.4-fold increase between 1973 and 2012 [2]), it is important to develop NEN disease models that more accurately reflect the biology of human NEN tissues in terms of diagnostic criteria and genetic alterations [89]. Much of the rise in incidence is thought to be the result of improved detection [2]. A greater diversity of model types and origins will help to address our understanding of these diseases in context of their increasing prevalence. All types of model systems are valuable at different parts of the drug screening and development process. Use and continued improvement of these models will drive preclinical advancements across the spectrum of neuroendocrine neoplasia.

Author Contributions: Conceptualization, J.d.R. and A.J.H.S.; data curation, A.J.H.S. and K.S.-A.; writing—original draft preparation, A.J.H.S., K.S.-A. and J.d.R.; writing—review and editing, K.E.L., N.R., S.K., P.H.E., K.P., E.B., D.E.Q., J.R.H., Y.P. and J.d.R.; supervision, J.d.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Intramural Research Program of the National Cancer Institute.

Acknowledgments: The authors would like to acknowledge Diana Varghese for her support in the drafting process.

Conflicts of Interest: D.E.Q. is currently receiving grant R01 CA260200 from the National Cancer Institute. Otherwise, the authors declare no conflict of interest.

References
1. Oronsky, B.; Ma, P.C.; Morgensztern, D.; Carter, C.A. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. *Neoplasia* 2017, 19, 991–1002. [CrossRef] [PubMed]
2. Dasari, A.; Shen, C.; Halperin, D.; Zhao, B.; Zhou, S.; Xu, Y.; Shih, T.; Yao, J.C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. *JAMA Oncol.* 2017, 3, 1335–1342. [CrossRef] [PubMed]
3. Raphael, M.J.; Chan, D.L.; Law, C.; Singh, S. Principles of Diagnosis and Management of Neuroendocrine Tumours. *CMAJ* 2017, 189, E398–E404. [CrossRef] [PubMed]
4. Jensen, R.T.; Bodei, L.; Capdevila, J.; Couvelard, A.; Falconi, M.; Glasberg, S.; Kloppel, G.; Lamberts, S.; Peeters, M.; Rindi, G.; et al. Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. *Neuroendocrinology* 2019, 108, 26–36. [CrossRef] [PubMed]
5. Rindi, G.; Mete, O.; Uccella, S.; Basturk, O.; La Rosa, S.; Brosens, L.A.A.; Ezzat, S.; de Herder, W.W.; Klimstra, D.S.; Papotti, M.; et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. *Endocr. Pathol.* 2022, 33, 115–154. [CrossRef] [PubMed]
6. Ma, Z.-Y.; Gong, Y.-F.; Zhuang, H.-K.; Zhou, Z.-X.; Huang, S.-Z.; Zou, Y.-P.; Huang, B.-W.; Sun, Z.-H.; Zhang, C.-Z.; Tang, Y.-Q.; et al. Pancreatic Neuroendocrine Tumors: A Review of Serum Biomarkers, Staging, and Management. *World J. Gastroenterol.* 2020, 26, 2305–2322. [CrossRef]
55. Faugeroux, V.; Pailler, E.; Oulhen, M.; Deas, O.; Brulle-Soumare, L.; Hervieu, C.; Marty, V.; Alexandrova, K.; Andree, K.C.; Stoecklein, N.H.; et al. Genetic Characterization of a Unique Neuroendocrine Transdifferentiation Prostate Circulating Tumor Cell-Derived ExPlant Model. *Nat. Commun.* 2020, 11, 1884. [CrossRef]

56. Okasho, K.; Mizuno, K.; Fukui, T.; Lin, Y.-Y.; Kameyama, Y.; Sunada, T.; Li, X.; Kimura, H.; Sumiyoshi, T.; Goto, T.; et al. Establishment and Characterization of a Novel Treatment-Related Neuroendocrine Prostate Cancer Cell Line KUCaP13. *Cancer Sci.* 2021, 112, 2781–2791. [CrossRef] [PubMed]

57. Tanaka, N.; Onda, M.; Seya, T.; Kanazawa, Y.; Naito, Z.; Asano, G.; Oguro, T. Establishment and Characterization of a Human Rectal Neuroendocrine Carcinoma Xenograft into Nude Mice. *Digestion* 1999, 60, 117–124. [CrossRef]

58. Takahashi, Y.; Onda, M.; Tanaka, N.; Seya, T. Establishment and Characterization of Two New Rectal Neuroendocrine Cell Carcinoma Cell Lines. *Digestion* 2000, 62, 262–270. [CrossRef] [PubMed]

59. Pfragner, R.; Wirnsberger, G.; Niederle, B.; Behmel, A.; Rinner, I.; Mandl, A.; Luo, J.; Adamiker, D.; Hoger, H.; et al. Establishment of a Continuous Cell Line from a Human Carcinoid of the Small Intestine (KRJ-I). *Int. J. Oncol.* 1996, 8, 513–520. [CrossRef]

60. Konno, H.; Arai, T.; Tanaka, T.; Baba, M.; Matsumoto, K.; Kanai, T.; Nakamura, S.; Baba, S.; Naito, Y.; Sugimura, H.; et al. Antitumor Effect of a Neutralizing Antibody to Vascular Endothelial Growth Factor on Liver Metastasis of Endocrine Neoplasm. *Jpn. J. Cancer Res.* 1998, 89, 933–939. [CrossRef]

61. Kölby, L.; Bernhardt, P.; Ahlman, H.; Wängberg, B.; Johanson, V.; Wigander, A.; Forsell-Aronsson, E.; Karlsson, S.; Ahrén, B.; Stennman, G.; et al. A Transplantable Human Carcinoid as Model for Somatostatin Receptor-Mediated and Amine Transporter-Mediated Radionuclide Uptake. *Am. J. Pathol.* 2001, 158, 745–755. [CrossRef]

62. Van Buren, G.; Rashid, A.; Yang, A.D.; Abdalla, E.K.; Gray, M.J.; Liu, W.; Somcio, R.; Fan, F.; Camp, E.R.; Yao, J.C.; et al. The Development and Characterization of a Human Midgut Carcinoid Cell Line. *Clin. Cancer Res.* 2007, 13, 4704–4712. [CrossRef]

63. Pfragner, R.; Behmel, A.; Höger, H.; Beham, A.; Ingolic, E.; Stelzer, I.; Svejda, B.; Moser, V.A.; Obenauf, A.C.; Siegl, V.; et al. Establishment and Characterization of Three Novel Cell Lines—PSTS, L-ST, H-ST—Derived from a Human Metastatic Midgut Carcinoid. *Anticancer Res.* 2009, 29, 1951–1961.

64. Yanagihara, K.; Kubo, T.; Mihara, K.; Kuvata, T.; Ochiai, T.; Seyama, T.; Yokozaki, H. Establishment of a Novel Cell Line from a Rare Human Duodenal Poorly Differentiated Neuroendocrine Carcinoma. *Oncotarget* 2018, 9, 36503–36514. [CrossRef]

65. Pfragner, R.; Höfler, H.; Behmel, A.; Ingolic, E.; Walser, V. Establishment and Characterization of Continuous Cell Line MTC-SK Derived from a Human Medullary Thyroid Carcinoma. *Cancer Res.* 1990, 50, 4160–4166.

66. April-Monn, S.L.; Wiedmer, T.; Skowronska, M.; Maire, R.; Schiavo Lena, M.; Trippel, M.; Di Domenico, A.; Muffatti, F.; Andreasi, V.; Capurso, G.; et al. Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. *Neuroendocrinology* 2021, 111, 273–287. [CrossRef]

67. Gragnoli, C. The CM Cell Line Derived from Liver Metastasis of Malignant Human Insulinoma Is Not a Valid Beta Cell Model for in Vitro Studies. *J. Cell. Physiol.* 2008, 216, 569–570. [CrossRef]

68. Lopez, J.R.; Claessens, S.M.H.; Macville, M.V.E.; Albrechts, J.C.M.; Skogseid, B.; Speel, E.-J.M. Spectral Karyotyping and Comparative Genomic Analysis of the Endocrine Pancreatic Tumor Cell Line BON-1. *Neuroendocrinology* 2010, 91, 131–141. [CrossRef]

69. Boora, G.K.; Kanwar, R.; Kulkarni, A.A.; Pleticha, J.; Ames, M.; Schroth, G.; Beutler, A.S.; Banck, M.S. Exome-Level Comparison of Primary Well-Differentiated Neuroendocrine Tumors and Their Cell Lines. *Cancer Genet.* 2015, 208, 374–381. [CrossRef]

70. Siddique, Z.-L.; Drozdov, I.; Floch, J.; Gustafsson, B.I.; Stenman, G.; et al. Defining an Appropriate Enterochromaffin Neuroendocrine Tumor Model. *Neuroendocrinology* 2009, 89, 458–470. [CrossRef]

71. Yanagihara, K.; Kubo, T.; Inoue, Y.; Mihara, K.; Morimoto, C.; Seyama, T.; Kuvata, T.; Ochiai, A.; Yokozaki, H. Development and Characterization of a Cancer Cachexia Model Employing a Rare Human Duodenal Neuroendocrine Carcinoma-Originating Cell Line. *Oncotarget* 2019, 10, 2435–2450. [CrossRef]

72. Hofving, T.; Arvidsson, Y.; Almobarak, B.; Inge, L.; Pfragner, R.; Persson, M.; Stennman, G.; Kristiansson, E.; Johanson, V.; Nilsson, O. The Neuroendocrine Phenotype, Genomic Profile and Therapeutic Sensitivity of GEPNET Cell Lines. *Endocr. Relat. Cancer* 2018, 25, 367–380. [CrossRef]

73. Alvarez, M.J.; Yan, P.; Alpaugh, M.L.; Bowden, M.; Sicinska, E.; Zhou, C.W.; Karan, C.; Realubit, R.B.; Mundi, P.S.; Grunn, A.; et al. Reply to ‘H-STS, L-STS and KRJ-I Are Not Authentic GEPNET Cell Lines’. *Nat. Genet.* 2019, 51, 1427–1428. [CrossRef]

74. Chen, Y.; Cang, S.; Han, L.; Liu, C.; Yang, P.; Solangi, Z.; Lu, Q.; Liu, D.; Chiao, J.W. Establishment of Prostate Cancer Spheres from a Prostate Cancer Cell Line after Phenethyl Isothiocyanate Treatment and Discovery of Androgen-Dependent Reversible Differentiation between Sphere and Neuroendocrine Cells. *Oncotarget* 2016, 7, 26567–26579. [CrossRef]

75. Chiao, J.W.; Hsieh, T.C.; Xu, W.; Sklarew, R.J.; Kanchler, R. Development of Human Prostate Cancer Cells to Neuroendocrine-like Cells by Interleukin-1. *Int. J. Oncol.* 1999, 15, 1033–1037. [CrossRef]

76. Shui, X.; Xu, R.; Zhang, C.; Meng, H.; Zhao, J.; Shi, C. Advances in Neuroendocrine Prostate Cancer Research: From Model Construction to Molecular Network Analyses. *Lab. Invest.* 2021, 102, 332–340. [CrossRef]

77. Florio, R.; De Lellis, L.; di Giacomo, V.; Di Marcantonio, M.C.; Cristiano, L.; Basile, M.; Verginelli, F.; Verzilli, D.; Ammazzalorso, A.; Prasad, S.C.; et al. Effects of PPARα Inhibition in Head and Neck Paraganglioma Cells. *PLoS ONE* 2017, 12, e0178995. [CrossRef]

78. Korpershoek, E.; Pacak, K.; Martiniowa, L. Murine Models and Cell Lines for the Investigation of Pheochromocytoma: Applications for Future Therapies? *Endocr. Pathol.* 2012, 23, 43–54. [CrossRef]
Kawasaki, K.; Toshimitsu, K.; Matano, M.; Fujita, M.; Fujii, M.; Togasaki, K.; Ebisudani, T.; Shimokawa, M.; Takano, A.; Takahashi, S.; et al. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. *Cell* 2020, 183, 1420–1435.e21. [CrossRef]

Fujii, M.; Shimokawa, M.; Date, S.; Takano, A.; Matano, M.; Nanki, K.; Ohta, Y.; Toshimitsu, K.; Nakazato, Y.; Kawasaki, K.; et al. A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. *Cell Stem Cell* 2016, 18, 827–838. [CrossRef]

Kim, M.; Mun, H.; Sung, C.O.; Cho, E.J.; Jeon, H.-J.; Chun, S.-M.; Jung, D.J.; Shin, T.H.; Jeong, G.S.; Kim, D.K.; et al. Patient-Derived Lung Cancer Organoids as in Vitro Cancer Models for Therapeutic Screening. *Nat. Commun.* 2019, 10, 3991. [CrossRef]

Gmeiner, W.H.; Miller, L.D.; Chou, J.W.; Dominjanni, A.; Mutkus, L.; Marini, F.; Ruiz, J.; Dotson, T.; Thomas, K.W.; Parks, G.; et al. Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10. *Cancers* 2020, 12, 788. [CrossRef]

Gao, D.; Vela, I.; Sboner, A.; Iaquinta, P.J.; Karthaus, W.R.; Gopalan, A.; Dowling, C.; Wanjala, J.N.; Undvall, E.A.; Arora, V.K.; et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer. *Cell* 2014, 159, 176–187. [CrossRef]

Puca, L.; Bareja, R.; Prandi, D.; Shaw, R.; Benelli, M.; Karthaus, W.R.; Hess, J.; Sigouros, M.; Donoghue, A.; Kossai, M.; et al. Patient-Derived Organoids to Model Rare Prostate Cancer Phenotypes. *Nat. Commun.* 2018, 9, 2404. [CrossRef]

Singh, N.; Rammarine, V.R.; Song, J.H.; Pandey, R.; Padi, S.K.R.; Nouri, M.; Olive, V.; Kobelev, M.; Okumura, K.; McCarthy, D.; et al. The Long Noncoding RNA H19 Regulates Tumor Plasticity in Neuroendocrine Prostate Cancer. *Nat. Commun.* 2021, 12, 7349. [CrossRef]

Mosquera, M.J.; Kim, S.; Bareja, R.; Fang, Z.; Cai, S.; Pan, H.; Asad, M.; Martin, M.L.; Sigouros, M.; Rowdo, F.M.; et al. Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. *Adv. Mater.* 2022, 34, e2100996. [CrossRef]

Dijkstra, K.K.; van den Berg, J.G.; Weeber, F.; van de Haar, J.; Velds, A.; Kaing, S.; Peters, D.D.G.C.; Eskens, F.A.L.M.; de Groot, D.J.A.; Tessaelaar, M.E.T.; et al. Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma. *Front. Endocrinol.* 2021, 12, 627819. [CrossRef]

Iwata, R.; Maruyama, M.; Ito, T.; Nakano, Y.; Kanemura, Y.; Koike, T.; Oe, S.; Yoshimura, K.; Nonaka, M.; Nomura, S.; et al. Establishment of a Tumor Sphere Cell Line from a Metastatic Brain Neuroendocrine Tumor. *Med. Mol. Morphol.* 2017, 50, 211–219. [CrossRef]

Kawasaki, K.; Fujii, M.; Sato, T. Gastroenteropancreatic Neuroendocrine Neoplasms: Genes, Therapies and Models. *Dis. Model. Mech.* 2018, 11, dmm029595. [CrossRef]

Choo, N.; Ramm, S.; Luu, J.; Winter, J.M.; Selth, L.A.; Frydenberg, M.; Grummet, J.; Sandhu, S.; Hickey, T.E.; et al. High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. *SLAS Discov.* 2021, 26, 1107–1124. [CrossRef]

Takács-Vellai, K.; Farkas, Z.; Ősz, F.; Stewart, G.W. Model Systems in SDHx-Related Pheochromocytoma/Paraganglioma. *Cancer Metastasis Rev.* 2021, 40, 1177–1201. [CrossRef]

Lepoutre-Lussey, C.; Thibault, C.; Buffet, A.; Morin, A.; Badoual, C.; Bénit, P.; Rustin, P.; Ottolenghi, C.; Janin, M.; Castro-Vega, L.-J.; et al. From Nf1 to Sdhb Knockout: Successes and Failures in the Quest for Animal Models of Pheochromocytoma. *Metastasis Rev.* 2021, 1177–1201. [CrossRef]

Powers, J.F.; Cochran, B.; Baleja, J.D.; Sikes, H.D.; Pattison, A.D.; Zhang, X.; Lomakin, I.; Shepard-Berry, A.; Pan, H.; et al. Identifies Topotecan as a Potential Chemotherapeutic Agent. *Front. Endocrinol.* 2012, 3, 1107–1124. [CrossRef]

Tsumura, R.; Koga, Y.; Hamada, A.; Suzuki, S.; Muto, I.; Nishimaki, T.; Suzuki, T.; Hatakeyama, K.; Tanaka, I.; Ikarashi, Y.; et al. Report of the Use of Patient-Derived Xenograft Models in the Development of Anticancer Drugs in Japan. *Cancer Sci.* 2020, 111, 3386–3394. [CrossRef]
101. Giffin, M.J.; Cooke, K.; Lobenhofer, E.K.; Estrada, J.; Zhan, J.; Deegen, P.; Thomas, M.; Murawsky, C.M.; Werner, J.; Liu, S.; et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. *Clin. Cancer Res.* 2021, 27, 1526–1537. [CrossRef] [PubMed]

102. Chamberlain, C.E.; German, M.S.; Yang, K.; Wang, J.; VanBroekhvin, H.; Regan, M.; Shokat, K.M.; Ducker, G.S.; Kim, G.E.; Hann, B.; et al. A Patient-Derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-Resistant Tumors. *Mol. Cancer Ther.* 2018, 17, 2702–2709. [CrossRef]

103. Powers, J.F.; Pacak, K.; Tischler, A.S. Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice. *Endocr. Pathol.* 2017, 28, 2–6. [CrossRef]

104. van Haften-Day, C.; Raghavan, D.; Russell, P.; Wills, E.J.; Gregory, P.; Tilley, W.; Horsfall, D.J. Xenografted Small Cell Undifferentiated Cancer of Prostate: Possible Common Origin with Prostatic Adenocarcinoma. *Prostate* 1987, 11, 271–279. [CrossRef]

105. Jelbart, M.E.; Russell, P.J.; Russell, P.; Wass, J.; Fullerton, M.; Wills, E.J.; Raghavan, D. Site-Specific Growth of the Prostate Xenograft Line UCRU-PR-2. *Prostate* 1989, 14, 163–175. [CrossRef]

106. Jelbart, M.E.; Russell, P.J.; Fullerton, M.; Russell, P.; Funder, J.; Raghavan, D. Ectopic Hormone Production by a Prostatic Small Cell Carcinoma Xenograft Line. *Mol. Cell. Endocrinol.* 1988, 55, 167–172. [CrossRef]

107. Pinthus, J.H.; Waks, T.; Schindler, D.G.; Harmelin, A.; Said, J.W.; Belidegrun, A.; Ramon, J.; Sheshar, Z. WISH-PC2: A Unique Xenograft Model of Human Prostatic Small Cell Carcinoma. *Cancer Res.* 2000, 60, 6563–6567. [CrossRef]

108. Agemy, L.; Harmelin, A.; Waks, T.; Leibovitch, I.; Rabin, T.; Pfeffer, M.R.; Sheshar, Z. Irradiation Enhances the Metastatic Potential of Prostatic Small Cell Carcinomas Xenografts. *Prostate* 2008, 68, 530–539. [CrossRef]

109. Aparicio, A.; Telephi, V.; Araujo, J.C.; Guo, C.C.; Liang, S.; Troncoso, P.; Logothetis, C.J.; Navone, N.M.; Maita, S. Neuroendocrine Prostate Cancer Xenografts with Large-Cell and Small-Cell Features Derived from a Single Patient’s Tumor: Morphological, Immunohistochemical, and Gene Expression Profiles. *Prostate* 2011, 71, 846–856. [CrossRef]

110. Palanisamy, N.; Yang, J.; Shepherd, P.D.A.; Li-Ning-Tapia, E.M.; Banerjee, A.; Mamno, G.C.; Araujo, J.C.; EIstathiou, E.; et al. The MD Anderson Prostate Cancer Patient-Derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-Driven Therapy Development. *Clin. Cancer Res.* 2020, 26, 4933–4946. [CrossRef]

111. Lin, D.; Wyatt, A.W.; Xue, H.; Wang, Y.; Dong, C.; Haegert, A.; Wu, R.; Brahmbhatt, S.; Mo, F.; Jong, L.; et al. High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. *Cancer Res.* 2014, 74, 1272–1283. [CrossRef] [PubMed]

112. Nguyen, H.M.; Vessella, R.L.; Morrissey, C.; Brown, L.G.; Coleman, I.M.; Higano, C.S.; Mostaghel, E.A.; Zhang, X.; True, L.D.; Lam, H.-M.; et al. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an–d Serve as Models for Evaluating Cancer Therapeutics. *Prostate* 2017, 77, 654–671. [CrossRef] [PubMed]

113. Risbridger, G.P.; Clark, A.K.; Porter, L.H.; Toivanen, R.; Bakshi, A.; Lister, N.L.; Pook, D.; Pezaro, C.J.; Sandhu, S.; Keerthikumar, S.; et al. The MURAL Collection of Prostate Cancer Patient-Derived Xenografts Enables Discovery through Preclinical Models of Uro-Oncology. *Nat. Commun.* 2021, 12, 5049. [CrossRef] [PubMed]

114. Lawrence, M.G.; Obinata, D.; Sandhu, S.; Selth, L.A.; Wong, S.Q.; Porter, L.H.; Lister, N.; Pook, D.; Pezaro, C.J.; Goode, D.L.; et al. Patient-Derived Models of Abiraterone- and Enzalutamide-Resistant Prostate Cancer Reveal Sensitivity to Ribosome-Directed Therapy. *Eur. Urol.* 2018, 74, 562–572. [CrossRef] [PubMed]

115. Zhang, L.; Yang, J.; Cai, J.; Song, X.; Deng, J.; Huang, X.; Chen, D.; Yang, M.; Wery, J.-P.; Li, S.; et al. A Subset of Gastric Cancers with EGFR Amplification and Overexpression Respond to Cetuximab Therapy. *Sci. Rep.* 2013, 3, 2992. [CrossRef]

116. Jiang, J.; Wang, D.D.; Yang, M.; Chen, D.; Pang, L.; Guo, S.; Cai, J.; Wery, J.-P.; Li, L.; Li, H.Q.; et al. Comprehensive Characterization of Chemotherapeutic Efficacy on Metastases in the Established Gastric Neuroendocrine Cancer Patient Derived Xenograft Model. *OncoTarget* 2015, 6, 15639–15651. [CrossRef]

117. Saunders, L.R.; Bankovich, A.J.; Anderson, W.C.; Aujay, M.A.; Bhedda, S.; Black, K.; Desai, R.; Escarpe, P.A.; Hampl, J.; Laysang, A.; et al. A DLL3-Targeted Antibody-Drug Conjugate Eradicates High-Grade Pulmonary Neuroendocrine Tumor-Initiating Cells in Vivo. *Sci. Transl. Med.* 2015, 7, 302ra136. [CrossRef] [PubMed]

118. Crona, J.; Skogseid, B. GEP- NETS UPDATE: Genetics of Neuroendocrine Tumors. *European Journal of Endocrinology* 2016, 174, R275–R290. [CrossRef]

119. Kersten, K.; de Visser, K.E.; van Miltenburg, M.H.; Jonkers, J. Genetically Engineered Mouse Models in Oncology Research and Cancer Medicine. *EMBO Mol. Med.* 2017, 9, 137–153. [CrossRef]

120. Lines, K.E.; Vas Nunes, R.P.; Frost, M.; Yates, C.J.; Stevenson, M.; Thakker, R.V. A MEN1 Pancreatic Neuroendocrine Tumour Mouse Model under Temporal Control. *Endocr. Connect.* 2017, 6, 232–242. [CrossRef]

121. Pelosi, G.; Sonzogni, A.; Harari, S.; Albini, A.; Bresaloe, E.; Marchio, C.; Massa, F.; Righi, L.; Gatti, G.; Papanikolaou, N.; et al. Classification of Pulmonary Neuroendocrine Tumors: New Insights. *Transl. Lung Cancer Res.* 2017, 6, 513–529. [CrossRef] [PubMed]

122. Gahete, M.D.; Jiménez-Vacas, J.M.; Alors-Pérez, E.; Herrero-Aguayo, V.; Fuentes-Fayos, A.C.; Pedraza-Arévalo, S.; Castaño, J.P.; Luque, R.M. Mouse Models of Endocrine Tumors. *J. Endocrinol.* 2019, 240, R73–R96. [CrossRef]

123. Thakker, R.V. Multiple Endocrine Neoplasia Type 1 (MEN1) and Type 4 (MEN4). *Mol. Cell. Endocrinol.* 2014, 386, 2–15. [CrossRef] [PubMed]
124. Jimenez, C.; Galg, R.F. Genetic Testing in Endocrinology: Lessons Learned from Experience with Multiple Endocrine Neoplasia Type 2 (MEN2). *Growth Horm. IGF Res.* 2004, 14, 150–157. [CrossRef] [PubMed]

125. Kalkan, E.; Waguespack, S.G. Endocrine Tumors Associated with Neurofibromatosis Type 1, Peutz-Jeghers Syndrome and Other Familial Neoplasia Syndromes. *Endocr. Tumor Syndr. Genet.* 2015, 41, 166–181. [CrossRef]

126. Heanue, T.A.; Boesmans, W.; Bell, D.M.; Kawakami, K.; Berghe, P.V.; Pachnis, V. A Novel Zebrafish Ret Heterozygous Model of Hirschsprung Disease Identifies a Functional Role for Mapk10 as a Modifier of Enteric Nervous System Phenotype Severity. *PloS Genet.* 2016, 12, e1006439. [CrossRef]

127. Elbialy, A.; Asakawa, S.; Watabe, S.; Kinoshita, S. A Zebrafish Acromegaly Model Elevates DNA Damage and Impairs DNA Repair Pathways. *Biologia* 2018, 7, 47. [CrossRef]

128. Zhu, S.; Lee, J.-S.; Guo, F.; Shin, J.; Perez-Atayde, A.R.; Kutok, J.L.; Rodig, S.J.; Neuberg, D.S.; Helman, D.; Feng, H.; et al. Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis. *Cancer Cell* 2019, 21, 362–373. [CrossRef]

129. Burzynski, G.; Shepherd, J.T.; Enomoto, H. Genetic Model System Studies of the Development of the Enteric Nervous System, Gut Motility and Hirschsprung’s Disease. *Neuropathol. Neurobiol.* 2009, 21, 113–127. [CrossRef]

130. Yang, H.W.; Kutok, J.L.; Lee, N.H.; Piao, H.Y.; Fletcher, C.D.M.; Kanki, J.P.; Look, A.T. Targeted Expression of Human MYCN Selectively Causes Pancreatic Neuroendocrine Tumors in Transgenic Zebrafish. *Cancer Res.* 2004, 64, 7256–7262. [CrossRef]

131. Liu, N.-A.; Jiang, H.; Ben-Shlomo, A.; Wawrowsky, K.; Fan, X.-M.; Lin, S.; Melmed, S. Targeting Zebrafish and Murine Pituitary Corticotroph Tumors with a Cyclin-Dependent Kinase (CDK) Inhibitor. *Proc. Natl. Acad. Sci. USA* 2011, 108, 8414–8419. [CrossRef] [PubMed]

132. van Rooijen, E.; Voest, E.E.; Logister, I.; Bussmann, J.; Korving, J.; van Eeden, F.J.; Giles, R.H.; Schulte-Merker, S. Von Hippel-Lindau Tumor Suppressor Mutants Faithfully Model Pathological Hypoxia-Driven Angiogenesis and Vascular Retinopathies in Zebrafish. *Dis. Models Mech.* 2010, 3, 343–353. [CrossRef] [PubMed]

133. Vitale, G.; Gaudenzi, G.; Dicitore, A.; Cotelli, F.; Ferone, D.; Persani, L. Zebrafish as an Innovative Model for Neuroendocrine Tumors. *Endocr.-Relat. Cancer* 2014, 21, R67–R83. [CrossRef] [PubMed]

134. Kim, S.-H.; Speirs, C.K.; Solnica-Krezel, L.; Ess, K.C. Zebrafish Model of Tuberous Sclerosis Complex Reveals Cell-Autonomous and Non-Cell-Autonomous Functions of Mutant Tuberin. *Dis. Models Mech.* 2011, 4, 255–267. [CrossRef] [PubMed]

135. Shin, J.; Padmanabhan, A.; de Groh, E.D.; Lee, J.-S.; Haidar, S.; Dahlberg, S.; Guo, F.; He, S.; Wolman, M.A.; Granato, M.; et al. Zebrafish Neurofibromatosis Type 1 Genes Have Redundant Functions in Tumorigenesis and Embryonic Development. *Dis. Models Mech.* 2012, 5, 881–894. [CrossRef]

136. Capdevila, J.; Casanova, O.; Salazar, R.; Castellano, D.; Segura, A.; Fuster, P.; Aller, J.; Garcia-Carbonero, R.; Jimenez-Fonseca, P.; Grande, E.; et al. Translational Research in Neuroendocrine Tumors: Pitfalls and Opportunities. *Oncologg 2017*, 36, 1899–1907. [CrossRef]

137. Zumsteg, A.; Strittmatter, K.; Klewe-Nebenius, D.; Antoniadis, H.; Christofori, G. A Bioluminescent Mouse Model of Pancreatic (beta)-Cell Carcinogenesis. *Carcinogenesis* 2010, 31, 1465–1474. [CrossRef]

138. Kobayashi, S.; Contractor, T.; Vosburgh, E.; Du, Y.-C.N.; Tang, L.H.; Clausen, R.; Harris, C.R. Alleles of Insml Determine Whether RIP1-Tag2 Mice Produce Insulinomas or Nonfunctioning Pancreatic Neuroendocrine Tumors. *Oncogenesis* 2019, 8, 16. [CrossRef]

139. Chun, M.G.H.; Mao, J.-H.; Chiu, C.W.; Balmain, A.; Hanahan, D. Polymorphic Genetic Control of Tumor Invasion in a Mouse Model of Pancreatic Neuroendocrine Carcinogenesis. *Nat. Protoc. Sci. USA* 2010, 107, 17268–17273. [CrossRef]

140. Wang, T.; Bonner-Weir, S.; Oates, P.S.; Chen, H.; Marusig, J.; Berber, A.; Schmidt, E.V.; Brand, S.J. Pancreatic Gastrin Model Elevates DNA Damage and Impairs DNA Repair Pathways. *Biologia* 2018, 7, 47. [CrossRef]

141. Elbialy, A.; Asakawa, S.; Watabe, S.; Kinoshita, S. A Zebrafish Acromegaly Model Elevates DNA Damage and Impairs DNA Repair Pathways. *Biologia* 2018, 7, 47. [CrossRef]

142. Friis-Hansen, L.; Sundler, F.; Li, Y.; Gillespie, P.J.; Saunders, T.L.; Greenenson, J.K.; Owyang, C.; Rehfeld, J.F.; Samuelson, L.C. Impaired Gastric Acid Secretion in Gastrin-Deficient Mice. *Am. J. Physiol.* 1998, 274, G561–G568. [CrossRef] [PubMed]

143. Grant, S.G.; Seidman, I.; Hanahan, D.; Bautch, V.L. Early Invasiveness Characterizes Metastatic Carcinoid Tumors in Transgenic Mice. *Cancer Res.* 1991, 51, 4917–4923. [PubMed]

144. Gum, J.R.; Hicks, J.W.; Crawley, S.C.; Yang, S.C.; Borowsky, A.D.; Dahl, C.M.; Kakar, S.; Kim, D.H.; Cardiff, R.D.; Kim, Y.S. Mice Expressing SV40 T Antigen Directed by the Intestinal Trefoil Factor Promoter Develop Tumors Resembling Human Small Cell Carcinoma of the Colon. *Mol. Cancer Res.* 2004, 2, 504–513. [CrossRef] [PubMed]

145. Gazdar, A.F.; Bunn, P.A.; Minna, J.D. Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward. *Nat. Rev. Cancer* 2017, 17, 725–737. [CrossRef]

146. Cui, M.; Augert, A.; Rongione, M.; Conkrite, K.; Parazzoli, S.; Nikitin, A.Y.; Ingolia, N.; MacPherson, D. PTEN Is a Potent Suppressor of Small Cell Lung Cancer. *Mol. Cancer Res.* 2014, 12, 654–659. [CrossRef]

147. McFadden, D.G.; Papagiannakopoulos, T.; Taylor-Weiner, A.; Stewart, C.; Carter, S.L.; Cibuulsks, K.; Bhutkar, A.; McKenna, A.; Dooley, A.; Vernon, A.; et al. Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing. *Cell* 2014, 156, 1298–1311. [CrossRef]

148. Wang, H.; Cui, J.; Yang, C.; Rosenblum, J.S.; Zhang, Q.; Song, Q.; Pang, Y.; Fang, F.; Sun, M.; Dmitriev, P.; et al. A Transgenic Mouse Model of Pacak—Zhuang Syndrome with An Epsa1 Gain-of-Function Mutation. *Cancers* 2019, 11, 667. [CrossRef]
172. Lewis, B.C.; Klimstra, D.S.; Varmus, H.E. The C-Myc and PyMT Oncogenes Induce Different Tumor Types in a Somatic Mouse Model for Pancreatic Cancer. *Genes Dev.* **2003**, *17*, 3127–3138. [CrossRef]

173. Neumann, C.A.; Krause, D.S.; Carman, C.V.; Das, S.; Dubey, D.P.; Abraham, J.L.; Bronson, R.T.; Fujiiwara, Y.; Orkin, S.H.; Van Etten, R.A. Essential Role for the Peroxiredoxin Prdx1 in Erythrocyte Antioxidant Defence and Tumour Suppression. *Nature* **2003**, *424*, 561–565. [PubMed]

174. Biondi, C.A.; Gartsidse, M.G.; Waring, P.; Loffler, K.A.; Stark, M.S.; Magnuson, M.A.; Kay, G.F.; Hayward, N.K. Conditional Inactivation of the Men1 Gene Leads to Pancreatic and Pituitary Tumorigenesis but Does Not Affect Normal Development of These Tissues. *Mol. Cell. Biol.* **2004**, *24*, 3125–3131. [CrossRef] [PubMed]

175. Loffler, K.A.; Biondi, C.A.; Gartsidse, M.G.; Serewko-Auret, M.M.; Duncan, R.; Tonks, I.D.; Mould, A.W.; Waring, P.; Muller, H.K.; Kay, G.F.; et al. Lack of Augmentation of Tumor Spectrum or Severity in Dual Heterozygous Men1 and Rb1 Knockout Mice. *Oncogene* **2007**, *26*, 4009–4017. [CrossRef] [PubMed]

176. Harding, B.; Lemos, M.C.; Reed, A.A.C.; Walls, G.V.; Jeyabalan, J.; Bowl, M.R.; Tatoossian, H.; Sullivan, N.; Hough, T.; Fraser, W.D.; et al. Multiple Endocrine Neoplasia Type 1 Knockout Mice Develop Parathyroid, Pancreatic, Pituitary and Adrenal Tumours with Hypercalcaemia, Hypophosphataemia and Hypercorticosteronaemia. *Endocr. Relat. Cancer* **2009**, *16*, 1313–1327. [CrossRef]

177. Lines, K.E.; Javid, M.; Reed, A.A.C.; Walls, G.V.; Stevenson, M.; Simon, M.; Kooblall, K.G.; Piret, S.E.; Christie, P.T.; Newey, P.J.; et al. Genetic Background Influences Tumour Development in Heterozygous Men1 Knockout Mice. *Endocr. Connect.* **2020**, *9*, 426–437. [CrossRef]

178. Shen, H.-C.J.; Ylaya, K.; Wilson, A.; Adem, A.; Hewitt, S.M.; Marx, S.J.; et al. Recapitulation of Pancreatic Neuroendocrine Tumors in Human Multiple Endocrine Neoplasia Type 1 Syndrome via Pdx1- Directed Inactivation of Men1. *Nature* **2009**, *496*, 1858–1866. [CrossRef]

179. Shen, H.-C.J.; Adem, A.; Ylaya, K.; Wilson, A.; He, M.; Lorang, D.; Hewitt, S.M.; Pechhold, K.; Harlan, D.M.; Lubensky, I.A.; et al. Deciphering von Hippel-Lindau (VHL/Vhl)-Associated Pancreatic Manifestations by Inactivating Vhl in Specific Pancreatic Cell Populations. *PLoS ONE* **2009**, *4*, e4897. [CrossRef] [PubMed]

180. Lu, J.; Herrera, P.L.; Carreira, C.; Bonnavion, R.; Seigne, C.; Calender, A.; Bertolino, P.; Zhang, C.X. Alpha Cell-Specific Men1 Ablation Triggers the Transdifferentiation of Glucagon-Expressing Cells and Insulinoma Development. *Gastroenterology* **2010**, *138*, 1954–1965. [CrossRef]

181. Shen, H.-C.J.; Ylaya, K.; Pechhold, K.; Wilson, A.; Adem, A.; Hewitt, S.M.; Libutti, S.K. Multiple Endocrine Neoplasia Type 1 Deletion in Pancreatic Alpha-Cells Leads to Development of Insulinomas in Mice. *Endocrinology* **2010**, *151*, 4024–4030. [CrossRef] [PubMed]

182. Yu, R.; Dhall, D.; Nissen, N.N.; Zhou, C.; Ren, S.-G. Pancreatic Neuroendocrine Tumors in Glucagon Receptor-Deficient Mice. *PLoS ONE* **2011**, *6*, e23397. [CrossRef] [PubMed]

183. Pei, X.-H.; Bai, F.; Li, Z.; Smith, M.D.; Whitelaw, G.; Jin, R.; Xiong, Y. Cytoplasmic CUL9/PARC Ubiquitin Ligase Is a Tumor Suppressor and Promotes P53-Dependent Apoptosis. *Cancer Res.* **2011**, *71*, 2969–2977. [CrossRef] [PubMed]

184. Quinn, T.J.; Yuan, Z.; Geha, R.; Vrikshajanani, C.; Koba, W.; Fine, E.; Hughes, D.T.; Schmid, H.A.; Libutti, S.K. Pasireotide (SOM230) Is Effective for the Treatment of Pancreatic Neuroendocrine Tumors (PNETs) in a Multiple Endocrine Neoplasia Type 1 (MEN1) Conditional Knockout Mouse Model. *Surgery* **2012**, *152*, 1068–1077. [CrossRef] [PubMed]

185. Singh, M.; Couto, S.S.; Forrest, W.; Lima, A.; Cheng, J.H.; Molina, R.; Long, J.E.; Hamilton, P.; McNutt, A.; Kasman, I.; et al. Anti-VEGF Antibody Therapy Does Not Promote Metastasis in Genetically Engineered Mouse Tumor Models. *J. Pathol.* **2012**, *227*, 417–430. [CrossRef]

186. Jones, H.B.; Reens, J.; Brocklehurst, S.R.; Betts, C.J.; Bickerton, S.; Bigley, A.L.; Jenkins, R.P.; Whalley, N.M.; Morgan, D.; Smith, D.M. Islets of Langerhans from Prohormone Convertase-2 Knockout Mice Show Elevated α-Cell Hyperplasia and Tumorigenesis with Elevated α-Cell Neogenesis. *Int. J. Exp. Pathol.* **2014**, *95*, 29–48. [CrossRef]

187. Glenn, S.T.; Jones, C.A.; Sexton, S.; LeVea, C.M.; Caraker, S.M.; Hajduczok, G.; Gross, K.W. Conditional Deletion of P53 and Rb in the Renin-Expressing Compartment of the Pancreas Leads to a Highly Penetrant Metastatic Pancreatic Neuroendocrine Carcinoma. *Oncogene* **2014**, *33*, 5706–5715. [CrossRef]

188. Takano, Y.; Kasai, K.; Takagishi, Y.; Kikumori, T.; Imai, T.; Murata, Y.; Hayashi, Y. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides. *PLoS ONE* **2015**, *10*, e0133812. [CrossRef] [PubMed]

189. Parisi, T.; Bronson, R.T.; Lees, J.A. Inactivation of the Retinoblastoma Gene Yields a Mouse Model of Malignant Colorectal Cancer. *Oncogene* **2015**, *34*, 5890–5899. [CrossRef] [PubMed]

190. Azzopardi, S.; Pang, S.; Klimstra, D.S.; Du, Y.-C.N. P53 and P16INK4a/P19ARF Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells. *Molecular Cells* **2016**, *36*, 610–617. [CrossRef]

191. Wong, C.; Tang, L.H.; Davidson, C.; Vosburgh, E.; Chen, W.; Foran, D.J.; Notterman, D.A.; Levine, A.J.; Xu, E.Y. Two Well-Differentiated Pancreatic Neuroendocrine Tumor Mouse Models. *Cell Death Differ.* **2020**, *27*, 269–283. [CrossRef] [PubMed]

192. Yamauchi, Y.; Kodama, Y.; Shiokawa, M.; Kakiuchi, N.; Marui, S.; Kusuda, T.; Sogabe, Y.; Tomono, T.; Mima, A.; Morita, T.; et al. Rb and P53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors. *Cancer Res.* **2020**, *80*, 3620–3630. [CrossRef] [PubMed]

193. Carter, A.M.; Kumar, N.; Herring, B.; Tan, C.; Guenter, R.; Telange, R.; Howse, W.; Viol, F.; McCaw, T.R.; Bickerton, H.H.; et al. Cdk5 Drives Formation of Heterogeneous Pancreatic Neuroendocrine Tumors. *Oncogenesis* **2021**, *10*, 83. [CrossRef] [PubMed]
194. Efрат, S.; Teitelman, G.; Anwar, M.; Ruggiero, D.; Hanahan, D. Glucagon Gene Regulatory Region Directs Oncoprotein Expression to Neurons and Pancreatic a Cells. *Neuron* **1988**, *1*, 605–613. [CrossRef]

195. Lee, Y.C.; Asa, S.L.; Drucker, D.J. Glucagon Gene 5′-Flanking Sequences Direct Expression of Simian Virus 40 Large T Antigen to the Intestine, Producing Carcinoma of the Large Bowel in Transgenic Mice. *J. Biol. Chem.* **1992**, *267*, 10705–10708. [CrossRef]

196. Asa, S.L.; Lee, Y.C.; Drucker, D.J. Development of Colonic and Pancreatic Endocrine Tumours in Mice Expressing a Glucagon-SV40 T Antigen Transgene. *Virchows Arch.* **1996**, *427*, 595–606. [CrossRef] [PubMed]

197. Williams, B.O.; Remington, L.; Albert, D.M.; Mukai, S.; Bronson, R.T.; Jacks, T. Cooperative Tumorigenic Effects of Germline Mutations in Rb and P53. *Nat. Genet.* **1994**, *7*, 480–484. [CrossRef]

198. Piret, S.E.; Thakker, R.V. Mouse Models for Inherited Endocrine and Metabolic Disorders. *J. Endocrinol.* **2011**, *211*, 211–230. [CrossRef]

199. Contractor, T.; Clausen, R.; Harris, G.R.; Rosenfeld, J.A.; Carpizo, D.R.; Tang, L.; Harris, C.R. IGF2 Drives Formation of Ileal Neuroendocrine Tumors in Patients and Mice. *Endocr. Relat. Cancer* **2020**, *27*, 175–186. [CrossRef]

200. Lopez, M.J.; Upchurch, B.H.; Rindi, G.; Leiter, A.B. Studies in Transgenic Mice Reveal Potential Relationships between Secretin-Producing Cells and Other Endocrine Cell Types. *J. Biol. Chem.* **1995**, *270*, 885–891. [CrossRef]

201. Asa, S.L.; Kovacs, K.; Stefanneau, L.; Horvath, E.; Billestrup, N.; Gonzalez-Manchon, C.; Vale, W. Pituitary Adenomas in Mice Transgenic for Growth Hormone-Releasing Hormone. *Endocrinology* **1992**, *131*, 2083–2089. [CrossRef] [PubMed]

202. Stefanneau, L.; Rindi, G.; Horvath, E.; Murphy, D.; Polak, J.M.; Kovacs, K. Morphology of Adenohypophysial Tumors in Mice Transgenic for Vasopressin-SV40 Hybrid Oncogene. *Endocrinology* **1992**, *130*, 1789–1795. [CrossRef]

203. Stenzel-Poore, M.P.; Cameron, V.A.; Vaughan, J.; Sawchenko, P.E.; Vale, W. Development of Cushing’s Syndrome in Corticotropin-Releasing Factor Transgenic Mice. *Endocrinology* **1992**, *130*, 3378–3386. [CrossRef] [PubMed]

204. Helseth, A.; Siegal, G.P.; Haug, E.; Bautch, V.L. Transgenic Mice That Develop Pituitary Tumors. A Model for Cushing’s Disease. *Am. J. Pathol.* **1992**, *140*, 1071–1080. [PubMed]

205. Low, M.J.; Liu, B.; Hammer, G.D.; Rubinstein, M.; Allen, R.G. Post-Translational Processing of Proopiomelanocortin (POMC) in Mouse Pituitary Melanotroph Tumors Induced by a POMC-Simian Virus 40 Large T Antigen Transgene. *J. Biol. Chem.* **1993**, *268*, 24967–24975. [CrossRef]

206. Fero, M.L.; Rivkin, M.; Tasch, M.; Porter, P.; Carow, C.E.; Firpo, E.; Polyak, K.; Tsai, L.-H.; Broudy, V.; Perlmutter, R.M.; et al. A Mouse Model of Multiple Endocrine Neoplasia, Type 1, Develops Multiple Neuroendocrine Tumors in Patients and Mice. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 11865–11870. [CrossRef]

207. Kiyokawa, H.; Kineman, R.D.; Manova-Todorova, K.O.; Soares, V.C.; Hoffman, E.S.; Ono, M.; Khanam, D.; Hayday, A.C.; Franklin, D.S.; Godfrey, V.L.; Lee, H.; Kovalev, G.I.; Schoonhoven, R.; Chen-Kiang, S.; Su, L.; Xiong, Y. CDK Inhibitors P18INK4c and P27kip-1 Null Mice: Analysis of Proteins Influencing P27kip-1 Ubiquitin Degradation. *Am. J. Pathol.* **2001**, *158*, 1118–1123. [CrossRef] [PubMed]

208. Nakayama, K.; Ishida, N.; Shirane, M.; Inomata, A.; Inoue, T.; Loh, D.Y.; Nakayama, K. Mice Lacking the Intestine, Producing Carcinoma of the Large Bowel in Transgenic Mice. *Neuron* **1988**, *1*, 721–732. [CrossRef]

209. Contractor, T.; Clausen, R.; Harris, G.R.; Rosenfeld, J.A.; Carpizo, D.R.; Tang, L.; Harris, C.R. IGF2 Drives Formation of Ileal Neuroendocrine Tumors in Patients and Mice. *Endocr. Relat. Cancer* **2020**, *27*, 175–186. [CrossRef]

210. Kumar, T.R.; Graham, K.E.; Asa, S.L.; Low, M.J. Simian Virus 40 T Antigen-Induced Gonadotroph Adenomas: A Model of Human Neuroendocrine Tumors in Patients and Mice. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 1118–1123. [CrossRef]

211. Vooijs, M.; Jonkers, J.; Lyons, S.; Berns, A. Flp-Mediated Tissue-Specific Inactivation of the Retinoblastoma Tumor Suppressor Gene in the Mouse. *Oncogene* **1996**, *15*, 1–12. [CrossRef] [PubMed]

212. Vooijs, M.; van der Valk, M.; Riele, H.T.; Berns, A. Flp-Mediated Tissue-Specific Inactivation of the Retinoblastoma Tumor Suppressor Gene in the Mouse. *Oncogene* **1996**, *15*, 733–744. [CrossRef]

213. Kiyokawa, H.; Kineman, R.D.; Manova-Todorova, K.O.; Soares, V.C.; Hoffman, E.S.; Ono, M.; Khanam, D.; Hayday, A.C.; Frohman, L.A.; Koff, A. Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of P27Kip1. *Cell* **1996**, *85*, 721–732. [CrossRef]

214. Fukushima, S.; Yasuda, S.; Ogawa, T.; Tanabe, K.; Oikawa, M.; Iida, Y.; Kajiyama, G.; Katsuyama, H.; Kato, M. CDK Inhibitors P18INK4c and P27Kip1 Mediate Two Separate Pathways to Collaboratively Suppress Pituitary Tumorogenesis. *Genes Dev.* **1998**, *12*, 2899–2911. [CrossRef]

215. Fedele, M.; Battista, S.; Kenyon, L.; Baldassarre, G.; Klein-Szanto, A.J.P.; Parlow, A.F.; Visone, R.; Pianeroti, G.M.; Outwater, E.; Santoro, M.; et al. Overexpression of the HMGA2 Gene in Transgenic Mice Leads to the Onset of Pituitary Adenomas. *Oncogene* **2002**, *21*, 3190–3198. [CrossRef]

216. Lloyd, R.V.; Ruebel, K.H.; Zhang, S.; Jin, L. Pituitary Hyperplasia in Glycoprotein Hormone Alpha Subunit-, P18INK4c-, and P27kip-1-Null Mice: Analysis of Proteins Influencing P27kip-1 Ubiquitin Degradation. *Am. J. Pathol.* **2002**, *160*, 1171–1179. [CrossRef]

217. Tsai, K.Y.; MacPherson, D.; Rubinstein, D.A.; Nikitin, A.Y.; Bronson, R.; Mercer, K.L.; Crowley, D.; Jacobs, T. ARF Mutation Accelerates Pituitary Tumor Development in Rb+/- Mice. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 16865–16870. [CrossRef]

218. Chandrasekharappa, S.C.; Marx, S.J.; et al. A Mouse Model of Multiple Endocrine Neoplasia, Type 1, Develops Multiple Endocrine Tumors. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 1118–1123. [CrossRef] [PubMed]

219. Santoro, M.; et al. Overexpression of the HMGA2 Gene in Transgenic Mice Leads to the Onset of Pituitary Adenomas. *Oncogene* **2002**, *21*, 3190–3198. [CrossRef] [PubMed]

220. Williams, B.O.; Remington, L.; Albert, D.M.; Mukai, S.; Bronson, R.T.; Jacks, T. Cooperative Tumorigenic Effects of Germline Mutations in Rb and P53. *Nat. Genet.* **1994**, *7*, 480–484. [CrossRef] [PubMed]

221. Asa, S.L.; Lee, Y.C.; Drucker, D.J. Development of Colonic and Pancreatic Endocrine Tumours in Mice Expressing a Glucagon-SV40 T Antigen Transgene. *Virchows Arch.* **1996**, *427*, 595–606. [CrossRef] [PubMed]

222. Lee, Y.C.; Asa, S.L.; Drucker, D.J. Glucagon Gene 5′-Flanking Sequences Direct Expression of Simian Virus 40 Large T Antigen to the Intestine, Producing Carcinoma of the Large Bowel in Transgenic Mice. *J. Biol. Chem.* **1992**, *267*, 10705–10708. [CrossRef] [PubMed]
Cancers 2022, 14, 5646

219. Zindy, F.; Nilsson, L.M.; Nguyen, L.; Meunier, C.; Smeyne, R.J.; Rehg, J.E.; Eberhart, C.; Sherr, C.J.; Roussel, M.F. Hemangiosarcomas, Medulloblastomas, and Other Tumors in Ink4c/P53-Null Mice. *Cancer Res.* 2003, 63, 5420–5427.

220. Fedele, M.; Pentimalli, F.; Baldassarre, G.; Battista, S.; Klein-Szanto, A.J.; Kenyon, L.; Visone, R.; De Martino, I.; Ciarmiello, A.; Arra, C.; et al. Transgenic Mice Overexpressing the Wild-Type Form of the HMGA1 Gene Develop Mixed Growth Hormone/Prolactin Cell Proliferative Anomalies and New Killer Cell Lymphomas. *Oncogene* 2005, 24, 3427–3435. [CrossRef]

221. Abbud, R.A.; Takumi, I.; Barker, E.M.; Ren, S.-G.; Chen, D.-Y.; Wawrowsky, K.; Melmed, S. Early Multipotential Pituitary Focal Hyperplasia in the α-Subunit of Glycoprotein Hormone-Driven Pituitary Tumor-Transforming Gene Transgenic Mice. *Mol. Endocrinol.* 2005, 19, 1383–1391. [CrossRef] [PubMed]

222. Donangelo, I.; Gutman, S.; Horvath, E.; Kovacs, K.; Wawrowsky, K.; Mount, M.; Melmed, S. Pituitary Tumor Transforming Gene Overexpression Facilitates Pituitary Tumor Development. *Endocrinology* 2006, 147, 4781–4791. [CrossRef] [PubMed]

223. Chesnokova, V.; Kovacs, K.; Castro, A.-V.; Zonis, S.; Melmed, S. Pituitary Hypoplasia in Pttg−/− Mice Is Protective for Rb+/− Pituitary Tumorigenesis. *Mol. Endocrinol.* 2005, 19, 2371–2379. [CrossRef]

224. Sotillo, R.; Renner, O.; Dubus, P.; Ruiz-Cabello, J.; Martin-Caballero, J.; Barbacid, M.; Carnero, A.; Malumbres, M. Cooperation between CdK4 and P27kip1 in Tumor Development: A Preclinical Model to Evaluate Cell Cycle Inhibitors with Therapeutic Activity. *Cancer Res.* 2005, 65, 3846–3852. [CrossRef] [PubMed]

225. Guidi, C.J.; Mudhasani, R.; Hoover, K.; Koff, A.; Leav, I.; Imbalzano, A.N.; Jones, S.N. Functional Interaction of the Retinoblastoma and In1/Snf5 Tumor Suppressors in Cell Growth and Pituitary Tumorigenesis. *Cancer Res.* 2006, 66, 8076–8082. [CrossRef]

226. Yin, Z.; Williams-Simons, L.; Parlow, A.F.; Asa, S.; Kirschner, L.S. Pituitary-Specific Knockout of the Carney Complex Gene Prkarla Leads to Pituitary Tumorigenesis. *Mol. Endocrinol.* 2008, 22, 380–387. [CrossRef]

227. Raitila, A.; Lehtonen, H.J.; Arola, J.; Heliövaara, E.; Ahlsten, M.; Georgitsi, M.; Jalanko, A.; Paetau, A.; Aaltonen, L.A.; Karhu, A. Mice with Inactivation of Aryl Hydrocarbon Receptor-Interacting Protein (Aip) Display Complete Penetrance of Pituitary Adenomas with Ablent ARNT Expression. *Am. J. Pathol.* 2010, 177, 1969–1976. [CrossRef]

228. Roussel-Gervais, A.; Biodeau, S.; Vallette, S.; Berthelet, F.; Lacroix-Arnaux, A.; Roy-Burman, P.; Drouin, J. Cooperation between Cyclin E and P27kip1 in Pituitary Tumorigenesis. *Mol. Endocrinol.* 2010, 24, 1835–1845. [CrossRef]

229. Bai, F.; Chan, H.L.; Smith, M.D.; Kiyokawa, H.; Pei, X.-H. P19Ink4d Is a Tumor Suppressor and Controls Pituitary Anterior Lobe Cell Proliferation. *Mol. Cell. Biol.* 2014, 34, 2121–2134. [CrossRef]

230. Bentley, L.; Esapa, C.T.; Nesbit, M.A.; Head, R.A.; Evans, H.; Lath, D.; Scudamore, C.L.; Hough, T.A.; Podrini, C.; Hannan, F.M.; et al. An N-Ethyl-N-Nitrosourea Induced Corticotropin-Releasing Hormone Promoter Mutation Provides a Mouse Model for Endogenous Glucocorticoid Excess. *Endocrinology* 2014, 155, 908–922. [CrossRef]

231. Harvey, M.; Vogel, H.; Lee, E.Y.; Bradley, A.; Donehower, L.A. Mice Deficient in Both P53 and Rb Develop Tumors Primarily of Endocrine Origin. *Cancer Res.* 1995, 55, 1146–1151. [PubMed]

232. Greenberg, N.M.; DeMayo, F.; Finegold, M.J.; Medina, D.; Tilley, W.D.; Aspinall, J.O.; Cunha, G.R.; Donjacour, A.A.; Matusik, R.J.; Rosen, J.M. Prostate Cancer in a Transgenic Mouse. *Proc. Natl. Acad. Sci. USA* 1995, 92, 3439–3443. [CrossRef]

233. Gingrich, J.R.; Barrios, R.; Morton, R.A.; Boyce, B.F.; DeMayo, F.J.; Finegold, M.J.; Angelopoulou, R.; Rosen, J.M.; Greenberg, N.M. Metastatic Prostate Cancer in a Transgenic Mouse. *Cancer Res.* 1996, 56, 4096–4102. [PubMed]

234. Kaplan-LeRko, P.J.; Chen, T.-M.; Ittmann, M.M.; Barrios, R.J.; Ayala, G.E.; Huss, W.J.; Maddison, L.A.; Foster, B.A.; Greenberg, N.M. Pathobiology of Autochthonous Prostate Cancer in a Pre-Clinical Transgenic Mouse Model. *Cancer Res.* 2005, 65, 219–237. [CrossRef]

235. Garabedian, E.M.; Humphrey, P.A.; Gordon, J.I. A Transgenic Mouse Model of Metastatic Prostate Cancer Originating from Neuroendocrine Cells. *Proc. Natl. Acad. Sci. USA* 1995, 92, 15382–15387. [CrossRef] [PubMed]

236. Gabri, M.Y.; Onita, T.; Ji, P.G.; Sakai, H.; Chan, F.L.; Koropatnick, J.; Chin, J.L.; Moussa, M.; Xuan, J.W. Prostate Targeting: PSP94 Gene Promoter/Enhancer Region Directed Prostate Tissue-Specific Expression in a Transgenic Mouse Prostate Cancer Model. *Gene Ther.* 2002, 9, 1589–1599. [CrossRef]

237. Gabri, M.Y.; Duan, W.; Wu, G.; Moussa, M.; Iawwa, J.I.; Panchal, C.J.; Sakai, H.; Xuan, J.W. A Novel Knock-in Prostate Cancer Model Demonstrates Biology Similar to That of Human Prostate Cancer and Suitable for Preclinical Studies. *Mol. Ther.* 2005, 11, 348–362. [CrossRef]

238. Klezovitch, O.; Chevillet, J.; Mirosovic, J.; Roberts, R.L.; Matusik, R.J.; Vasioukhin, V. Hepsin Promotes Prostate Cancer Progression and Metastasis. *Cancer Cell* 2004, 6, 185–195. [CrossRef]

239. Duan, W.; Gabri, M.Y.; Moussa, M.; Chan, F.L.; Sakai, H.; Fong, G.; Xuan, J.W. Knockin of SV40 Tag Oncogene in a Mouse Adenocarcinoma of the Prostate Model Demonstrates Advantageous Features over the Transgenic Model. *Oncogene* 2005, 24, 1510–1524. [CrossRef]

240. Zhou, Z.; Flesken-Nikitin, A.; Corney, D.C.; Wang, W.; Goodrich, D.W.; Roy-Burman, P.; Nikitin, A.Y. Synergy of P53 and Rb Deficiency in a Conditional Mouse Model for Metastatic Prostate Cancer. *Cancer Res.* 2006, 66, 7889–7898. [CrossRef]

241. Perez-Stable, C.; Altman, N.H.; Brown, J.; Harbison, M.; Cray, C.; Roos, B.A. Prostate, Adrenocortical, and Brown Adipose Tumors in Fetal Globin/T Antigen Transgenic Mice. *Lab. Invest.* 1996, 74, 363–373. [PubMed]

242. Perez-Stable, C.; Altman, N.H.; Mehta, P.P.; Delfos, L.J.; Roos, B.A. Prostate Cancer Progression, Metastasis, and Gene Expression in Transgenic Mice. *Cancer Res.* 1997, 57, 900–906. [PubMed]

243. Reiner, T.; de las Pozas, A.; Parrondo, R.; Perez-Stable, C. Progression of Prostate Cancer from a Subset of P63-Positive Basal Epithelial Cells in FG/Tag Transgenic Mice. *Mol. Cancer Res.* 2007, 5, 1171–1179. [CrossRef] [PubMed]
244. Libutti, S.K.; Crabtree, J.S.; Lorang, D.; Burns, A.L.; Mazzanti, C.; Hewitt, S.M.; O’Connor, S.; Ward, J.M.; Emmert-Buck, M.R.; Remaley, A.; et al. Parathyroid Gland-Specific Deletion of the Mouse Men1 Gene Results in Parathyroid Neoplasia and Hypercalcemic Hyperparathyroidism. Cancer Res. 2000, 60, 3125–3129. [PubMed]

245. Czeh, M.; Loddenkemper, C.; Shalapour, S.; Schön, C.; Robine, S.; Goldscheid, E.; Stein, H.; Schüler, T.; Willimsky, G.; Blankenstein, T. The Immune Response to Sporadic Colorectal Cancer in a Novel Mouse Model. Oncogene 2010, 29, 6591–6602. [CrossRef] [PubMed]

246. Seale, P.F.; Thomas, D.P.; Faulkner, K.B.; Tinsley, J.M. Stomach Cancer in Transgenic Mice Expressing Human Papillomavirus Type 16 Early Region Genes from a Keratin Promoter. J. Gen. Virol. 1994, 75 Pt 5, 1125–1137. [CrossRef]

247. Syder, A.J.; Karam, S.M.; Mills, J.C.; Ippolito, J.E.; Ansari, H.R.; Farook, V.; Gordon, J.I. A Transgenic Mouse Model of Metastatic Carcinoma Involving Transdifferentiation of a Gastric Epithelial Lineage Progenitor to a Neuroendocrine Phenotype. Proc. Natl. Acad. Sci. USA 2004, 101, 4471–4476. [CrossRef]

248. Veniaminova, N.A.; Hayes, M.M.; Varney, J.M.; Merchant, J.L. Conditional Deletion of Menin Results in Antral G Cell Hyperplasia and Gastric Carcinoids. Gut 2017, 66, 1012–1021. [CrossRef] [PubMed]

249. Michiels, F.-M.; Chappuis, S.; Caillou, B.; Pasini, A.; Talbot, M.; Monier, R.; Feunteun, J.; Billaud, M. Development of Thyroid Predisposes to the Development of Follicular Carcinomas with a Higher Incidence in Females. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 58–66. [CrossRef] [PubMed]

250. Calvete, O.; Varro, A.; Pritchard, D.M.; Barroso, A.; Oteo, M.; Morcillo, M.Á.; Vargiu, P.; Dodd, S.; Garcia, M.; Reyes, J.; et al. A Knockin Mouse Model for Human ATP4aR703C Mutation Identified in Familial Gastric Neuroendocrine Tumors Recapitulates the Premalignant Condition of the Human Disease and Suggests New Therapeutic Strategies. Dis. Model. Mech. 2016, 9, 975–984. [CrossRef]

251. Sundaresan, S.; Kang, A.J.; Hayes, M.M.; Choi, E.-Y.K.; Merchant, J.L. Deletion of Men1 and Somatostatin Induces Hypergastrinemia and Gastric Carcinoids. Am. J. Pathol. 2000, 157, 671–677. [CrossRef]

252. Michiels, F.-M.; Chappuis, S.; Caillou, B.; Pasini, A.; Talbot, M.; Monier, R.; Feunteun, J.; Billaud, M. Development of Medullary Thyroid Carcinoma in Transgenic Mice Expressing the RET Protooncogene Altered by a Multiple Endocrine Neoplasia Type 2A Mutation. Proc. Natl. Acad. Sci. USA 1997, 94, 3330–3335. [CrossRef] [PubMed]

253. Powell, D.J.; Russell, J.P.; Nibu, K.; Li, G.; Rhee, E.; Liao, M.; Goldstein, M.; Keane, W.M.; Santoro, M.; Fusco, A.; et al. The RET/PTC3 Fusion Protein: Metastatic Solid-Type Papillary Carcinomas in Murine Thyroids. Cancer Res. 1998, 58, 5523–5528. [PubMed]

254. Cho, J.-Y.; Sagartz, J.E.; Capen, C.C.; Mazzalferri, E.L.; Jhiang, S.M. Early Cellular Abnormalities Induced by RET/PTC1 Oncogene in Thyroid-Targeted Transgenic Mice. Oncogene 1999, 18, 3659–3665. [CrossRef] [PubMed]

255. La Perle, K.M.D.; Jhiang, S.M.; Capen, C.C. Loss of P53 Promotes Anaplasia and Local Invasion in Ret/PTC1-Induced Thyroid Carcinoma. Am. J. Pathol. 2000, 157, 671–677. [CrossRef]

256. Acton, D.S.; Velthuizen, D.; Lips, C.J.; Hoppener, J.W. Multiple Endocrine Neoplasia Type 2B Mutation in Human RET Oncogene Induces Medullary Thyroid Carcinoma in Transgenic Mice. Oncogene 2000, 19, 3121–3125. [CrossRef]

257. Powell, D.J.; Russell, J.P.; Cunnane, M.; Greco, A.; Portella, G.; Santoro, M.; Fusco, A.; Rothstein, J.L. The TRK-T1 Fusion Protein Induces Neoplastic Transformation of Thyroid Epithelium. Oncogene 2000, 19, 5729–5735. [CrossRef]

258. Powell, D.J.; Russell, J.P.; Li, G.; Kuo, B.A.; Fidanza, V.; Huebner, K.; Rothstein, J.L. Altered Gene Expression in Immunogenic Poorly Differentiated Thyroid Tumors from RET/PTC3p53 Mice. Cancer Res. 2000, 60, 3121–3125. [CrossRef]

259. Suzuki, H.; Willingham, M.C.; Cheng, S. Mice with a Mutation in the Thyroid Hormone Receptor β Gene Spontaneously Develop Thyroid Carcinoma: A Mouse Model of Thyroid Carcinogenesis. Thyroid 2002, 12, 963–969. [CrossRef]

260. Ribeiro-Neto, F.; Leon, A.; Urbani-Brocad, J.; Lou, L.; Nyska, A.; Altschuler, D.L. CAMP-Dependent Oncogenic Action of Rap1b in the Thyroid Gland. J. Biol. Chem. 2004, 279, 46868–46875. [CrossRef]

261. Vitagliano, D.; Portella, G.; Troncone, G.; Francione, A.; Rossi, C.; Bruno, A.; Giorgini, A.; Coluzzi, S.; Nappi, T.C.; Rothstein, J.L.; et al. Thyroid Targeting of the N-Ras(Gln61Lys) Oncogene in Transgenic Mice Results in Follicular Tumors That Progress to Poorly Differentiated Carcinomas. Oncogene 2006, 25, 5467–5474. [CrossRef] [PubMed]

262. Pestourie, C.; Thézé, B.; Kuhnst, B.; Le Helleix, S.; Gombert, K.; Dollé, F.; Tavitian, B.; Duong-F. PET Imaging of Medullary Thyroid Carcinoma in MEN2A Transgenic Mice Using 6-{[(18)F]F-L-DOPA. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 58–66. [CrossRef] [PubMed]

263. Yeager, N.; Klein-Szanto, A.; Kimura, S.; Di Cristofano, A. Pten Loss in the Mouse Thyroid Causes Goiter and Follicular Adenomas: Insights into Thyroid Function and Cowden Disease Pathogenesis. Cancer Res. 2007, 67, 959–966. [CrossRef] [PubMed]

264. Antico-Arciuch, V.G.; Dima, M.; Liao, X.-H.; Refetoff, S.; Di Cristofano, A. Cross-Talk between PI3K and Estrogen in the Mouse Thyroid Predisposes to the Development of Follicular Carcinomas with a Higher Incidence in Females. Oncogene 2010, 29, 5678–5686. [CrossRef]

265. Chakravarty, D.; Santos, E.; Ryder, M.; Knauf, J.A.; Liao, X.-H.; West, B.L.; Bollag, G.; Kolesnick, R.; Thin, T.H.; Rosen, N.; et al. Small-Molecule MAPK Inhibitors Restore Radioiodine Incorporation in Mouse Thyroid Cancers with Conditional BRAF Activation. J. Clin. Investig. 2011, 121, 4700–4711. [CrossRef]

266. Dobson, M.E.; Diao-Krou, E.; Grachtchouk, V.; Yu, J.; Colby, L.A.; Wilkinson, J.E.; Giordano, T.J.; Koenig, R.J. Pioglitazone Induces a Proadipogenic Antitumor Response in Mice with PAX8-PPARY Fusion Protein Thyroid Carcinoma. Endocrinology 2011, 152, 4455–4465. [CrossRef]
267. Arciuch, V.G.A.; Russo, M.A.; Dima, M.; Kang, K.S.; Dasrath, F.; Liao, X.-H.; Refetoff, S.; Montagna, C.; Cristofano, A.D.
Thyrocyte-Specific Inactivation of P53 and Pten Results in Anaplastic Thyroid Carcinomas Faithfully Recapitulating Human Tumors. Oncotarget 2011, 2, 1109–1126. [CrossRef]

268. Pringle, D.R.; Yin, Z.; Lee, A.A.; Manchanda, P.K.; Yu, L.; Parlow, A.F.; Jarjoura, D.; Perle, K.M.D.L.; Kirschner, L.S. Thyroid-Specific Ablation of the Carney Complex Gene, PRKAR1A, Results in Hyperthyroidism and Follicular Thyroid Cancer. Endocr.-Relat. Cancer 2012, 19, 435–446. [CrossRef]

269. Pozo, K.; Castro-Rivera, E.; Tan, C.; Plattner, F.; Schwach, G.; Siegl, V.; Meyer, D.; Guo, A.; Gundara, J.; Mettlach, G.; et al. The Role of Cdk5 in Neuroendocrine Thyroid Cancer. Cancer Cell 2013, 24, 499–511. [CrossRef]

270. Zhu, X.; Zhao, L.; Park, J.W.; Willingham, M.C.; Cheng, S. Synergistic Signaling of KRAS and Thyroid Hormone Receptor β Mutants Promotes Undifferentiated Thyroid Cancer through MYC Up-Regulation. Neoplasia 2014, 16, 757–769. [CrossRef]

271. Charles, R.-P.; Silva, J.; Iezza, G.; Phillips, W.A.; McMahon, M. Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis. Mol. Cancer Res. 2014, 12, 979–986. [CrossRef] [PubMed]

272. McFadden, D.G.; Vernon, A.; Santiago, P.M.; Martinez-McFaline, R.; Bhutkar, A.; Crowley, D.M.; McMahon, M.; Sadow, P.M.; Jacks, T. P53 Constrains Progression to Anaplastic Thyroid Carcinoma in a Braf-Mutant Mouse Model of Papillary Thyroid Cancer. Proc. Natl. Acad. Sci. USA 2014, 111, E1600–E1609. [CrossRef] [PubMed]

273. Shappell, S.B.; Thomas, G.V.; Roberts, R.L.; Herbert, R.; Ittmann, M.M.; Rubin, M.A.; Humphrey, P.A.; Sundberg, J.P.; Rozengurt, N.; Barrios, R.; et al. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004, 64, 2270–2305. [CrossRef]

274. Rickman, D.S.; Beltran, H.; Demichelis, F.; Rubin, M.A. Biology and Evolution of Poorly Differentiated Neuroendocrine Tumors. Nat. Med. 2017, 23, 664–673. [CrossRef] [PubMed]

275. Berman-Booty, L.D.; Knudsen, K.E. Models of Neuroendocrine Prostate Cancer. Endocr.-Relat. Cancer 2015, 22, R33–R49. [CrossRef]

276. Masumori, N.; Thomas, T.Z.; Chaurand, P.; Case, T.; Paul, M.; Kasper, S.; Caprioli, R.M.; Tsukamoto, T.; Shappell, S.B.; Matusik, R.J. A Probasin-Large T Antigen Transgenic Mouse Line Develops Prostate Adenocarcinoma and Neuroendocrine Carcinoma with Metastatic Potential1. Cancer Res. 2001, 61, 2239–2249.

277. Bayley, J.-P.; van Minderhout, I.; Hogendoorn, P.C.W.; Cornelisse, C.J.; van der Wal, A.; Prins, F.A.; Teppema, L.; Dahan, A.; Devilee, P.; Taschner, P.E.M. Sdhd and Sdhd/H19 Knockout Mice Do Not Develop Paraganglioma or Pheochromocytoma. PLoS ONE 2009, 4, e7987. [CrossRef]